<SEC-DOCUMENT>0001571049-15-001620.txt : 20150304
<SEC-HEADER>0001571049-15-001620.hdr.sgml : 20150304
<ACCEPTANCE-DATETIME>20150304120723
ACCESSION NUMBER:		0001571049-15-001620
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20150303
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150304
DATE AS OF CHANGE:		20150304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		15672364

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1500497_8-k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;<B>&nbsp;</B>&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 18pt Times New Roman, Times, Serif"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Date of Report (Date of earliest event reported):
March 3, 2015</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Exact name of registrant as specified in
its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="width: 30%; font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>Delaware</b></font></td>
    <TD STYLE="width: 40%; font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>0-50626</b></font></td>
    <TD STYLE="width: 30%; font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>91-1707622</b></font></td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>(State or other jurisdiction</b></font></td>
    <TD STYLE="font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>(Commission File Number)</b></font></td>
    <TD STYLE="font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>(IRS Employer</b></font></td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>of incorporation)</b></font></td>
    <TD>&nbsp;</td>
    <TD STYLE="font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>Identification No.)</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>200 Connell Drive, Suite 1500</B><BR>
<B>Berkeley Heights, NJ 07922 </B><BR>
<B>(Address of principal executive offices and zip code) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Registrant&rsquo;s telephone number, including
area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>obligation of the registrant under any of the following provisions
(<I>see </I>General Instruction A.2. below): </B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) </B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) </B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) </B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) </B></FONT></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item&nbsp;1.01.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Entry Into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">On March 3, 2015,
Cyclacel Pharmaceuticals, Inc. (the &ldquo;<B>Company</B>&rdquo;) agreed to sell an aggregate of 10,000,000
shares of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;<B>Common Stock</B>&rdquo;) in a registered
public offering, at a price to the public of $1.00 per share (the &ldquo;<B>Offering</B>&rdquo;), for a total gross proceeds for
the Company of $10.0 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">On March 3, 2015,
the Company entered into an engagement letter (the &ldquo;<B>Engagement Letter</B>&rdquo;) with H.C. Wainwright&nbsp;&amp; Co.,
LLC (the &ldquo;<B>Placement Agent</B>&rdquo;), pursuant to which the Placement Agent serves as the exclusive placement agent
and sole book-runner for the Company in connection with the public offering on a reasonable best efforts basis. In connection
with the Offering, the Company also entered into a securities purchase agreement (the &ldquo;<B>Securities Purchase Agreement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The Company
expects net proceeds from the sale of the Common Stock, after deducting for the placement agent fees and other offering
expenses, to be approximately $9.2  million. The Offering is expected to close on March 9, 2015, subject to customary
closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The Offering is being
made pursuant to the Company&rsquo;s effective shelf registration statement on Form&nbsp;S-3 and an accompanying prospectus (Registration
No. 333-187801) filed with the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) on April 8, 2013 and declared
effective by the SEC on April 22, 2013, and a preliminary and final prospectus supplement filed with the SEC in connection with
the Company&rsquo;s takedown relating to the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">Pursuant to the Engagement
Letter, the Company has also agreed to indemnify the Placement Agent and certain other persons against certain liabilities relating
to or arising out of the Placement Agent&rsquo;s activities under the Engagement Letter. The Securities Purchase Agreement contains
customary representations, warranties, covenants, closing conditions and indemnification and termination provisions, including
for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The Engagement Letter
and the Securities Purchase Agreement include certain representations, warranties and covenants that the parties made to, and solely
for the benefit of, the other in the context of all of the terms and conditions of that agreement and in the context of the specific
relationship between the parties. The provisions of the Engagement Letter and the Securities Purchase Agreement, including the
representations and warranties contained therein, are not for the benefit of any party other than the parties to such agreements
and are not intended as documents for investors and the public to obtain factual information about the current state of affairs
of the parties to those documents and agreements. Rather, investors and the public should look to other disclosures contained in
the Company&rsquo;s filings with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The foregoing descriptions
of the material terms of the Engagement Letter and the Securities Purchase Agreement do not purport to be complete and are qualified
in their entirety by reference to the Engagement Letter, attached hereto as Exhibit 1.1, and the Form of Securities Purchase Agreement,
attached hereto as Exhibit 10.1. Each of the Engagement Letter and the Form of Securities Purchase Agreement is incorporated herein
by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A copy of the opinion of
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. relating to the legality of the issuance and sale of the shares of Common Stock
in the Offering is attached as Exhibit 5.1 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 8.01</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On March 3, 2015, the Company issued a press
release announcing the launching of the Offering. On March 4, 2015, the Company issued a press release announcing, among other
things, the pricing of the Offering. A copy of each press release is attached hereto as Exhibits 99.1 and 99.2, respectively, and
is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Neither the filing of the press releases as
exhibits to this Current Report on Form 8-K nor the inclusion in the press releases of a reference to the Company&rsquo;s internet
address shall, under any circumstances, be deemed to incorporate the information available at the Company&rsquo;s internet address
into this Current Report on Form 8-K. The information available at the Company&rsquo;s internet address is not part of this Current
Report on Form 8-K or any other report filed by it with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item&nbsp;9.01</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">(d) The following exhibits are filed with
this Report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><B>Exhibit</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><B>No.</B></FONT></P></td>
    <TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></td>
    <TD STYLE="width: 89%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>Exhibit</B></FONT></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">1.1</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Engagement Letter, dated March 3, 2015, by and between Cyclacel Pharmaceuticals, Inc. and H.C. Wainwright &amp; Co., LLC.</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">5.1</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.1</font></td>
    <td>&nbsp;</td>
    <td><FONT STYLE="font-size: 10pt">Form of Securities Purchase Agreement, by and between Cyclacel Pharmaceuticals, Inc.</FONT></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">23.1</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in the opinion filed as Exhibit 5.1).</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">99.1</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Press Release, dated March 3, 2015, announcing the launching of the Offering. </font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">99.2</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Press release, dated March 4, 2015, announcing the pricing of the Offering.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt"><b>CYCLACEL PHARMACEUTICALS, INC.</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 53%">&nbsp;</td>
    <td style="width: 6%"><font style="font-size: 10pt">By: </font></td>
    <td style="width: 41%; border-bottom: Black 1pt solid"><font style="font-size: 10pt">/s/ Paul McBarron</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Name:</font></td>
    <td><font style="font-size: 10pt">Paul McBarron</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Title:</font></td>
    <td><font style="font-size: 10pt">Executive Vice President&mdash;Finance, </font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer and Chief Operating</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Officer</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 4, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>t1500497_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><img src="ex1-1logo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right; margin-right: 1in">March 3, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>STRICTLY CONFIDENTIAL</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Spiro Rombotis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">200 Connell Drive #1500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Berkeley Heights, NJ 07922</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dear Spiro:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This letter agreement (this
&ldquo;<U>Agreement</U>&rdquo;) constitutes the agreement between Cyclacel Pharmaceuticals, Inc. (the &ldquo;<U>Company</U>&rdquo;)
and H.C. Wainwright &amp; Co., LLC (&ldquo;<U>Wainwright</U>&rdquo;) that Wainwright shall serve as the exclusive agent, advisor
or underwriter in the offering (each, an &ldquo;<U>Offering</U>&rdquo;) of securities of the Company (&ldquo;<U>Securities</U>&rdquo;)
during the Term (as defined below) of this Agreement. The terms of the Offering and the Securities issued in connection therewith
shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or
authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It
is understood that Wainwright&rsquo;s assistance in the Offering will be subject to the satisfactory completion of such investigation
and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal
approvals of Wainwright in connection with the transaction. The Company expressly acknowledges and agrees that Wainwright&rsquo;s
involvement in the Offering is strictly on a reasonable best efforts basis and that the consummation of the Offering will be subject
to, among other things, market conditions. The execution of this Agreement does not constitute a commitment by Wainwright to purchase
the Securities and does not ensure a successful Offering of the Securities or the success of Wainwright with respect to securing
any other financing on behalf of the Company. Wainwright may retain other brokers, dealers, agents or underwriters on its behalf
in connection with an Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation;
Reimbursement</U>. At the closing of each Offering (each, a &ldquo;<U>Closing</U>&rdquo;), the Company shall compensate Wainwright
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Cash
Fee</I>. The Company shall pay to Wainwright a cash fee, or as to an underwritten Offering an underwriter discount, equal to 7%
of the aggregate gross proceeds raised in each Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Expense
Allowance</I>. Out of the proceeds of each Closing, the Company also agrees to pay Wainwright a non-accountable expense allowance
of $50,000 (<U>provided</U>, <U>however</U>, that such reimbursement amount in no way limits or impairs the indemnification and
contribution provisions of this Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Tail
Fee</I>. Wainwright shall be entitled to compensation under clause (1) hereunder, calculated in the manner set forth therein,
with respect to any public or private offering or other financing or capital raising transaction of any kind (&ldquo;<U>Tail Financing</U>&rdquo;)
to the extent that such financing or capital is provided to the Company by investors whom Wainwright has contacted and introduced,
directly or indirectly, to the Company during the Term, if such Tail Financing is consummated at any time within the 3-month period
following the expiration or termination of this Agreement, other than&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #474746">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #474746">430 Park Avenue | New York,
New York 10022 | 212.356.0500 | www.hcwco.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #474746">Member: FINRA/SIPC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">existing shareholders of the Company,
including Eastern Capital Ltd, Sarissa Capital Management LP, Aspire Capital Fund LLC or their affiliated funds, as to which no
such tail compensation shall be payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Term and Termination
of Engagement; Exclusivity</U>. The term of Wainwright&rsquo;s exclusive engagement will begin on the date hereof and end 20 days
after the date hereof (the &ldquo;<U>Term</U>&rdquo;). Notwithstanding anything to the contrary contained herein, the Company agrees
that the provisions relating to the payment of fees, reimbursement of expenses, indemnification and contribution, confidentiality,
conflicts, independent contractor and waiver of the right to trial by jury will survive any termination of this Agreement. During
Wainwright&rsquo;s engagement hereunder: (i) the Company will not, and will not permit its representatives to, other than in coordination
with Wainwright, contact or solicit institutions, corporations or other entities or individuals as potential purchasers of the
Securities and (ii) the Company will not pursue any financing transaction which would be in lieu of the Offering. Furthermore,
the Company agrees that during Wainwright&rsquo;s engagement hereunder, all inquiries, whether direct or indirect, from prospective
investors will be referred to Wainwright and will be deemed to have been contacted by Wainwright in connection with the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Information; Reliance</U>.
The Company shall furnish, or cause to be furnished, to Wainwright all information requested by Wainwright for the purpose of rendering
services hereunder (all such information being the &ldquo;<U>Information</U>&rdquo;). In addition, the Company agrees to make available
to Wainwright upon request from time to time the officers, directors, accountants, counsel and other advisors of the Company. The
Company recognizes and confirms that Wainwright (a) will use and rely on the Information, including any documents provided to investors
in the Offering (the &ldquo;<U>Offering Documents</U>&rdquo; which shall include any Purchase Agreements (as defined below), and
on information available from generally recognized public sources in performing the services contemplated by this Agreement without
having independently verified the same; (b) does not assume responsibility for the accuracy or completeness of the Offering Documents
or the Information and such other information; and (c) will not make an appraisal of any of the assets or liabilities of the Company.
Upon reasonable request, the Company will meet with Wainwright or its representatives to discuss all information relevant for disclosure
in the Offering Documents and will cooperate in any investigation undertaken by Wainwright thereof, including any document included
or incorporated by reference therein. At each Offering, at the request of Wainwright, the Company shall deliver such legal letters,
comfort letters and officer&rsquo;s certificates, all in form and substance reasonably satisfactory to Wainwright and its counsel
as is customary for such Offering. Wainwright shall be a third party beneficiary of any representations, warranties, covenants
and closing conditions made by the Company in any Offering Documents, including representations, warranties, covenants and closing
conditions made to any investor in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Related Agreements</U>.
At each Offering, the Company shall enter into the following additional agreements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Underwritten
Offering</I>. If the Offering is an underwritten Offering, the Company and Wainwright shall enter into a customary underwriting
agreement in form and substance satisfactory to Wainwright and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Best
Efforts Offering</I>. If the Offering is on a best efforts basis, the sale of Securities to the investors in the Offering will
be evidenced by a purchase agreement (&ldquo;<U>Purchase Agreement</U>&rdquo;) between the Company and such investors in a form
reasonably satisfactory to the Company and Wainwright. Prior to the signing of any Purchase Agreement, officers of the Company
with responsibility for financial affairs will be available to answer inquiries from prospective investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Escrow
and Settlement</I>. In respect of the Offering, the Company and Wainwright shall enter into an escrow agreement with a third party
escrow agent, which may also be Wainwright&rsquo;s clearing agent, pursuant to which Wainwright&rsquo;s compensation and expenses
shall be paid from the gross</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0">proceeds of the
Securities sold. If the Offering is settled in whole or in part via delivery versus payment (&ldquo;DVP&rdquo;), Wainwright shall
arrange for its clearing agent to provide the funds to facilitate such settlement. The Company shall bear the cost of the escrow
agent and shall reimburse Wainwright for the actual out of pocket cost of such clearing agent settlement and financing, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>FINRA
Amendments</I>. Notwithstanding anything herein to the contrary, in the event that Wainwright determines that any of the terms
provided for hereunder shall not comply with a FINRA rule, including but not limited to FINRA Rule 5110, then the Company shall
agree to amend this Agreement (or include such revisions in the final underwriting) in writing upon the request of Wainwright to
comply with any such rules; provided that any such amendments shall not provide for terms that are less favorable to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality</U>.
In the event of the consummation or public announcement of the Offering, Wainwright shall have the right to disclose its participation
in the Offering, including, without limitation, the Offering at its cost of &ldquo;tombstone&rdquo; advertisements in financial
and other newspapers and journals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnity</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection
with the Company&rsquo;s engagement of Wainwright as Offering agent, the Company hereby agrees to indemnify and hold harmless Wainwright
and its affiliates, and the respective controlling persons, directors, officers, members, shareholders, agents and employees of
any of the foregoing (collectively the &ldquo;<U>Indemnified Persons</U>&rdquo;), from and against any and all claims, actions,
suits, proceedings (including those of shareholders), damages, liabilities and expenses incurred by any of them (including the
reasonable fees and expenses of counsel), as incurred, (collectively a &ldquo;<U>Claim</U>&rdquo;), that are (A) related to or
arise out of (i) any actions taken or omitted to be taken (including any untrue statements made or any statements omitted to be
made) by the Company, or (ii) any actions taken or omitted to be taken by any Indemnified Person in connection with the Company&rsquo;s
engagement of Wainwright, or (B) otherwise relate to or arise out of Wainwright&rsquo;s reasonable activities on the Company&rsquo;s
behalf under Wainwright&rsquo;s engagement, and the Company shall reimburse any Indemnified Person for all expenses (including
the reasonable fees and expenses of counsel) as incurred by such Indemnified Person in connection with investigating, preparing
or defending any such claim, action, suit or proceeding, whether or not in connection with pending or threatened litigation in
which any Indemnified Person is a party. The Company will not, however, be responsible for any Claim that is finally judicially
determined to have resulted from the gross negligence or willful misconduct of any person seeking indemnification for such Claim.
The Company further agrees that no Indemnified Person shall have any liability to the Company for or in connection with the Company&rsquo;s
engagement of Wainwright except for any Claim incurred by the Company as a result of such Indemnified Person&rsquo;s gross negligence
or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company
further agrees that it will not, without the prior written consent of Wainwright, settle, compromise or consent to the entry of
any judgment in any pending or threatened Claim in respect of which indemnification may be sought hereunder (whether or not any
Indemnified Person is an actual or potential party to such Claim), unless such settlement, compromise or consent includes an unconditional,
irrevocable release of each Indemnified Person from any and all liability arising out of such Claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly
upon receipt by an Indemnified Person of notice of any complaint or the assertion or institution of any Claim with respect to which
indemnification is being sought hereunder, such Indemnified Person shall notify the Company in writing of such complaint or of
such assertion or institution but failure to so notify the Company shall not relieve the Company from any obligation it may have
hereunder, except and only to the extent such failure results in the forfeiture by the Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">of substantial rights and defenses.
If the Company so elects or is requested by such Indemnified Person, the Company will assume the defense of such Claim, including
the employment of counsel reasonably satisfactory to such Indemnified Person and the payment of the fees and expenses of such counsel.
In the event, however, that legal counsel to such Indemnified Person reasonably determines that having common counsel would present
such counsel with a conflict of interest or if the defendant in, or target of, any such Claim, includes an Indemnified Person and
the Company, and legal counsel to such Indemnified Person reasonably concludes that there may be legal defenses available to it
or other Indemnified Persons different from or in addition to those available to the Company, then such Indemnified Person may
employ its own separate counsel to represent or defend him, her or it in any such Claim and the Company shall pay the reasonable
fees and expenses of such counsel. Notwithstanding anything herein to the contrary, if the Company fails timely or diligently to
defend, contest, or otherwise protect against any Claim, the relevant Indemnified Party shall have the right, but not the obligation,
to defend, contest, compromise, settle, assert crossclaims, or counterclaims or otherwise protect against the same, and shall be
fully indemnified by the Company therefor, including without limitation, for the reasonable fees and expenses of its counsel and
all amounts paid as a result of such Claim or the compromise or settlement thereof. In addition, with respect to any Claim in which
the Company assumes the defense, the Indemnified Person shall have the right to participate in such Claim and to retain his, her
or its own counsel therefor at his, her or its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company
agrees that if any indemnity sought by an Indemnified Person hereunder is held by a court to be unavailable for any reason then
(whether or not Wainwright is the Indemnified Person), the Company and Wainwright shall contribute to the Claim for which such
indemnity is held unavailable in such proportion as is appropriate to reflect the relative benefits to the Company, on the one
hand, and Wainwright on the other, in connection with Wainwright&rsquo;s engagement referred to above, subject to the limitation
that in no event shall the amount of Wainwright&rsquo;s contribution to such Claim exceed the amount of fees actually received
by Wainwright from the Company pursuant to Wainwright&rsquo;s engagement. The Company hereby agrees that the relative benefits
to the Company, on the one hand, and Wainwright on the other, with respect to Wainwright&rsquo;s engagement shall be deemed to
be in the same proportion as (a) the total value paid or proposed to be paid or received by the Company pursuant to the applicable
Offering (whether or not consummated) for which Wainwright is engaged to render services bears to (b) the fee paid or proposed
to be paid to Wainwright in connection with such engagement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&rsquo;s
indemnity, reimbursement and contribution obligations under this Agreement (a) shall be in addition to, and shall in no way limit
or otherwise adversely affect any rights that any Indemnified Party may have at law or at equity and (b) shall be effective whether
or not the Company is at fault in any way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">G.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation of
Engagement to the Company</U>. &nbsp;The Company acknowledges that Wainwright has been retained only by the Company, that Wainwright
is providing services hereunder as an independent contractor (and not in any fiduciary or agency capacity) and that the Company&rsquo;s
engagement of Wainwright is not deemed to be on behalf of, and is not intended to confer rights upon, any shareholder, owner or
partner of the Company or any other person not a party hereto as against Wainwright or any of its affiliates, or any of its or
their respective officers, directors, controlling persons (within the meaning of Section 15 of the Securities Act or Section 20
of the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), employees or agents. Unless otherwise
expressly agreed in writing by Wainwright, no one other than the Company is authorized to rely upon this Agreement or any other
statements or conduct of Wainwright, and no one other than the Company is intended to be a beneficiary of this Agreement. The Company
acknowledges that any recommendation or advice, written or oral, given by Wainwright to the Company in connection with Wainwright&rsquo;s
engagement is intended solely for the benefit and use of the Company&rsquo;s management and directors in considering a possible
Offering, and any such recommendation or advice is not on behalf of, and shall not confer any rights or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">remedies upon, any other person or be used
or relied upon for any other purpose. Wainwright shall not have the authority to make any commitment binding on the Company. The
Company, in its sole discretion, shall have the right to reject any investor introduced to it by Wainwright.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">H.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation of
Wainwright&rsquo;s Liability to the Company</U>. &nbsp;Wainwright and the Company further agree that neither Wainwright nor any of its
affiliates or any of its their respective officers, directors, controlling persons (within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act), employees or agents shall have any liability to the Company, its security holders or creditors,
or any person asserting claims on behalf of or in the right of the Company (whether direct or indirect, in contract, tort, for
an act of negligence or otherwise) for any losses, fees, damages, liabilities, costs, expenses or equitable relief arising out
of or relating to this Agreement or the services rendered hereunder, except for losses, fees, damages, liabilities, costs or expenses
that arise out of or are based on any action of or failure to act by Wainwright and that are finally judicially determined to have
resulted solely from the gross negligence or willful misconduct of Wainwright.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>.
&nbsp;This Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to agreements
made and to be fully performed therein. Any disputes that arise under this Agreement, even after the termination of this Agreement,
will be heard only in the state or federal courts located in the City of New York, State of New York. The parties hereto expressly
agree to submit themselves to the jurisdiction of the foregoing courts in the City of New York, State of New York. The parties
hereto expressly waive any rights they may have to contest the jurisdiction, venue or authority of any court sitting in the City
and State of New York. In the event Wainwright or any Indemnified Person is successful in any action, or suit against the Company,
arising out of or relating to this Agreement, the final judgment or award entered shall be entitled to have and recover from the
Company the costs and expenses incurred in connection therewith, including its reasonable attorneys&rsquo; fees. <FONT STYLE="letter-spacing: -0.15pt">Any
rights to trial by jury with respect to any such action, proceeding or suit are hereby waived by Wainwright and the Company. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">J.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. &nbsp;All
notices hereunder will be in writing and sent by certified mail, hand delivery, overnight delivery or fax, if sent to Wainwright,
to H. C. Wainwright &amp; Co. LLC, at the address set forth on the first page hereof, e-mail: notices@hcwco.com, Attention: Head
of Investment Banking, and if sent to the Company, to the address set forth on the first page hereof, fax number (866) 271-3466
Attention: President and Chief Executive Officer with a copy to fax number: +44 1382 206 067, Attention EVP, Finance &amp; COO.
Notices sent by certified mail shall be deemed received five days thereafter, notices sent by hand delivery or overnight delivery
shall be deemed received on the date of the relevant written record of receipt, and notices delivered by fax shall be deemed received
as of the date and time printed thereon by the fax machine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">K.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conflicts</U>.
&nbsp;The Company acknowledges that Wainwright and its affiliates may have and may continue to have investment banking and other relationships
with parties other than the Company pursuant to which Wainwright may acquire information of interest to the Company. Wainwright
shall have no obligation to disclose such information to the Company or to use such information in connection with any contemplated
transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">L.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Anti-Money Laundering</U>.
&nbsp;To help the United States government fight the funding of terrorism and money laundering, the federal laws of the United States
requires all financial institutions to obtain, verify and record information that identifies each person with whom they do business.
This means we must ask you for certain identifying information, including a government-issued identification number (e.g., a U.S.
taxpayer identification number) and such other information or documents that we consider appropriate to verify your identity, such
as certified articles of incorporation, a government-issued business license, a partnership agreement or a trust instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">M.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.
&nbsp;The Company represents and warrants that it has all requisite power and authority to enter into and carry out the terms and provisions
of this Agreement and the execution, delivery and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">performance of this Agreement does not breach
or conflict with any agreement, document or instrument to which it is a party or bound. This Agreement shall not be modified or
amended except in writing signed by Wainwright and the Company. This Agreement shall be binding upon and inure to the benefit of
both Wainwright and the Company and their respective assigns, successors, and legal representatives. This Agreement constitutes
the entire agreement of Wainwright and the Company with respect to this Offering and supersedes any prior agreements with respect
to the subject matter hereof. If any provision of this Agreement is determined to be invalid or unenforceable in any respect, such
determination will not affect such provision in any other respect, and the remainder of the Agreement shall remain in full force
and effect. This Agreement may be executed in counterparts (including facsimile counterparts), each of which shall be deemed an
original but all of which together shall constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">*********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In acknowledgment that
the foregoing correctly sets forth the understanding reached by Wainwright and the Company, please sign in the space provided below,
whereupon this letter shall constitute a binding Agreement as of the date indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">Very truly yours,</font></td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD COLSPAN="2"><font style="font-size: 10pt"><b>H.C. WAINWRIGHT &amp; CO., LLC</b></font></td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="width: 56%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 39%">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD STYLE="padding-bottom: 1pt"><font style="font-size: 10pt">By</font></td>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;&nbsp;<font style="font-size: 10pt">/s/ Mark Viklund</font></td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">Name: Mark Viklund</font></td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">Title: Chief Executive Officer</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accepted and Agreed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>CYCLACEL
PHARMACEUTICALS, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 5%; text-align: justify"><font style="font-size: 10pt">By</font></td>
    <TD STYLE="vertical-align: bottom; width: 45%; border-bottom: Black 1pt solid; text-align: justify; padding-left: 0.125in"><font style="font-size: 10pt">/s/ Spiro Rombotis</font></td>
    <td style="vertical-align: top; width: 50%; text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">Name: Spiro Rombotis</font></td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">Title: President &amp; Chief Executive Officer</font></td>
    <td style="vertical-align: top; text-align: justify">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>t1500497_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: 0.1pt; text-align: right"><FONT STYLE="letter-spacing: 0.4pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><img src="ex5-1logo.jpg"></FONT></TD>
    <TD STYLE="width: 50%"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">666
        Third Avenue</FONT></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">New
        York, New York 10017</FONT></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">212-935-3000</FONT></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">212-983-3115
        fax</FONT></P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">www.mintz.com</FONT></P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">March 4, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">200 Connell Drive, Suite 1500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Berkeley Heights, NJ 07922</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 37.05pt">This opinion is furnished to you in connection
with the sale and issuance by Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), of up to 10,000,000
shares of the Company&rsquo;s common stock, par value $0.001 (the &ldquo;Common Stock&rdquo;), in a public offering pursuant to
the Registration Statement on Form S-3 (Registration Statement No. 333-187801), filed with the Securities and Exchange Commission
(the &ldquo;Commission&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;), on April 23, 2013 and declared
effective by the Commission on April 22, 2013 (the &ldquo;Registration Statement&rdquo;), the related prospectus included in the
Registration Statement (the &ldquo;Base Prospectus&rdquo;), and the prospectus supplement relating to the shares of Common Stock
to be filed with the Commission pursuant to Rule 424(b) promulgated under the Act (the &ldquo;Prospectus Supplement&rdquo; and,
together with the Base Prospectus, the &ldquo;Prospectus&rdquo;). All of the shares of Common Stock are to be issued and sold by
the Company as described in the Registration Statement and Prospectus and pursuant to that certain Securities Purchase Agreement,
dated March 3, 2015, by and between the Company and the purchasers named therein (the &ldquo;Securities Purchase Agreement&rdquo;).
The Securities Purchase Agreement has been filed as exhibit 10.1 to a Current Report on Form 8-K dated March 4, 2015, as filed
with the Commission on the date hereof and incorporated by reference into the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 37.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 37.05pt">In connection with this opinion, we have examined
and relied on the originals or copies, certified or otherwise identified to our satisfaction, of all such corporate records of
the Company and such other instruments and other certificates of public officials, officers and representatives of the Company
and such other persons, and we have made such investigations of law, as we have deemed appropriate as a basis for the opinion expressed
below. In our examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity
of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified
or photostatic copies and the authenticity of the originals of such copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 37.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 37.05pt">Based upon the foregoing, and subject to the
limitations set forth below, we are of the opinion that the shares of Common Stock, when issued by the Company and delivered by
the Company against payment therefor as contemplated by the Securities Purchase Agreement, will be validly issued, fully paid and
non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 37.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 37.05pt">Our opinion is limited to the General Corporation
Law of the State of Delaware and the United States federal laws, and we express no opinion with respect to the laws of any other
jurisdiction. No opinion is expressed</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps; letter-spacing: 0.4pt">Boston
| Washington | New York | Stamford | Los Angeles | San Francisco | San Diego | London </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-variant: small-caps">Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">March 4, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Page </FONT>2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">herein with respect to the qualification of the shares of Common
Stock under the securities or blue sky laws of any state or any foreign jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 37.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 37.05pt">Please note that we are opining only as to
the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently
existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any
of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 37.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 37.05pt">We hereby consent to the filing of this opinion
with the Commission as an exhibit to a Current Report on Form 8-K and the Registration Statement in accordance with the requirements
of Item 601(b)(5) of Regulation S-K under the Act and to the use of this Firm&rsquo;s name therein and in the Prospectus Supplement
under the caption &ldquo;Legal Matters.&rdquo; In giving such consent, we do not hereby admit that we are in the category of persons
whose consent is required under Section 7 of the Act or the rules and regulations of the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 37.05pt">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%">&nbsp;</td>
    <td style="width: 50%; font-size: 10pt"><font style="font-size: 10pt">Very truly yours,</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt"><font style="font-size: 10pt">/s/ Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>t1500497_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><B>SECURITIES
PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Securities Purchase
Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of March 3, 2015, between Cyclacel Pharmaceuticals, Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including its
successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the
terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act of
1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), the Company desires to issue and sell to each Purchaser, and each Purchaser,
severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of
which are hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>ARTICLE I.</B><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the
meanings set forth in this Section 1.1:</P>

<P STYLE="color: red; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Shares pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii)
the Company&rsquo;s obligations to deliver the Shares, in each case, have been satisfied or waived, but in no event later than
the third Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; means Mintz, Levin, Cohn, Ferris, Glovsky &amp; Popeo, P.C., with offices located at 666 Third Avenue, New York,
NY 10017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Escrow
Agent</U>&rdquo; means Signature Bank, a New York State chartered bank, with offices at 261 Madison Avenue, New York, New York
10016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Escrow
Agreement</U>&rdquo; means the escrow agreement entered into prior to the Closing Date, by and among the Company, the Escrow Agent
and H. C. Wainwright &amp; Co., LLC pursuant to which the Purchasers shall deposit Subscription Amounts with the Escrow Agent to
be applied to the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(r).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock, options or other stock based awards to employees, consultants,
officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee
members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose
for services rendered to the Company, (b) securities upon the exercise or exchange of or conversion of any securities exercisable
or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that
such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations)
or to extend the term of such securities, (c) securities issued pursuant to any of the Company&rsquo;s agreements and/or obligations
existing on the date of this Agreement, and (d) securities issued pursuant to acquisitions or strategic transactions approved by
a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a Person (or to the
equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business
synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">investment of funds, but shall not
include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose
primary business is investing in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(gg).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(gg).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(z).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(o).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a material lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(m).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $1.00, subject to adjustment for reverse and forward stock splits, stock dividends, stock
combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(gg).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means H. C. Wainwright &amp; Co., LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with
the Commission and delivered by the Company to each Purchaser at the Closing in connection with the issuance of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission (file No. 333-187801) which registers the sale
of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Regulation
FD</U>&rdquo; means Regulation FD promulgated by the Commission pursuant to the Exchange Act, as such Regulation may be amended
or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the
same purpose and effect as such Regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include the location and/or reservation of borrowable shares of Common Stock).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares purchased hereunder as specified below
such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U>, and shall, where applicable, also include any direct
or indirect subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New
York Stock Exchange or the OTCQB or OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement and any other documents or agreements executed in connection with the transactions contemplated
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means American Stock Transfer &amp; Trust Company, the current transfer agent of the Company, with a mailing address
of 59 Maiden Lane, New York, New York and a facsimile number of 718-236-4588, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>ARTICLE II.</B><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution
and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly,
agree to purchase, up to an aggregate of $10,000,000 of Shares. Each Purchaser shall deliver to the Escrow Agent, via wire transfer
or a certified check, immediately available funds equal to such Purchaser&rsquo;s Subscription Amount as set forth on the signature
page hereto executed by such Purchaser and the Company shall deliver to each Purchaser its respective Shares, and the Company and
each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants
and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of EGS or such other location as the parties
shall mutually agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Deliveries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
legal opinion of Company Counsel, in such form and substance reasonably satisfactory to the Placement Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via
The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) Shares equal to such Purchaser&rsquo;s
Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company or the Escrow Agent, as applicable,
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement duly executed by such Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
Escrow Agent, such Purchaser&rsquo;s Subscription Amount by wire transfer to the account specified in the Escrow Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
Conditions</U>.<U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as
of a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being
met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein
(unless as of a specific date therein);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg
L.P. shall not have been suspended</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">or limited, or minimum
prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall
a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred
any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect
on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser,
makes it impracticable or inadvisable to purchase the Shares at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>ARTICLE III.</B><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Company</U>. The Company hereby makes the following representations and warranties to each Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
&nbsp;All of the direct and indirect subsidiaries of the Company are set forth on the SEC Reports. The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar
rights to subscribe for or purchase securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization
and Qualification</U>. &nbsp;The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation,
bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business
and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
the case may be, would not reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability
of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, or condition (financial
or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s
ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or
(iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and to the Company&rsquo;s knowledge, no Proceeding has been instituted
in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">and each of the
other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have
been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board
of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other than in connection with the Required
Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been)
duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and
binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general
equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by
applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Shares and the consummation by it of the transactions contemplated hereby and
thereby do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate
or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any
of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration
or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing
a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which
any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court
or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)
and (iii), such as would not reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)
the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement,
(iii) application(s) to each applicable Trading Market for the listing of the Shares for trading thereon in the time and manner
required thereby and (iv) such filings as are required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required
Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of the Shares; Registration</U>. The Shares are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the
Company. The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act,
which became effective on&nbsp;April 22, 2013 (the &ldquo;<U>Effective Date</U>&rdquo;), including the Prospectus, and such amendments
and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under
the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or
preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted
or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of
the Commission, shall file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement and
any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and
any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not
and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at time
the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material
respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were
made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>.
Except as disclosed in the Registration Statement, the Prospectus or the Prospectus Supplement, the Company has not issued any
capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to its existing agreement
with Aspire Capital Fund LLC (&ldquo;<B>Aspire</B>&rdquo;), the exercise of employee stock options under the Company&rsquo;s stock
option plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans
and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed
periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or
any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase
and sale of the Shares and as disclosed in the SEC Reports, there are no outstanding options, warrants, scrip rights to subscribe
to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable
or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock
of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become
bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and
sale of the Shares will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person
(other than the Purchasers) and will not result in a right of any holder of Company securities to adjust the exercise,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">conversion, exchange
or reset price under any of such securities. Except as disclosed in the SEC Reports, there are no outstanding securities or instruments
of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings
or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary.
The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan
or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and
nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was
issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or
authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Shares. Except
as disclosed in the SEC Reports, there are no stockholders agreements, voting agreements or other similar agreements with respect
to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any
of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof,
for the one year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such
material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with
the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on
a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration
of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of
the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the Company
included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations
of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance
with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company
and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods
then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, except as specifically disclosed in a subsequent SEC Reports filed prior to the date hereof, (i) there
has been no event, occurrence or development that has had or that would</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">reasonably be expected
to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than
(A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities
not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the
Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem
any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate,
except pursuant to existing Company stock option plans. The Company does not have pending before the Commission any request for
confidential treatment of information. Except for the issuance of the Shares contemplated by this Agreement, no material event,
liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with
respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial
condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation
is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is
made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>.
Except as disclosed in the SEC Reports, there is no material action, suit, inquiry, notice of violation, proceeding or investigation
pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective
properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county,
local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;) which (i) adversely affects or challenges the legality, validity
or enforceability of any of the Transaction Documents or the Shares or (ii) would, if there were an adverse judgment, reasonably
be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof,
is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws
or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission
has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or
any Subsidiary under the Exchange Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of
the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or
any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure
or proprietary information agreement or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">non-competition
agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment
of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of
the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws
and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except
where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the
Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is
bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any
court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation
of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental
protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case of
clauses (i) through (iii), as would not reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental
Laws</U>. The Company and its Subsidiaries (i) are in compliance with
all federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient
air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases
or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous
Materials</U>&rdquo;) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment,
storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand
letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated
or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have received all permits licenses or other approvals required
of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms
and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could
be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits would not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">neither the Company
nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not
materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens
for the payment of federal, state or other taxes, for which appropriate reserves have been made in accordance with GAAP and, the
payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company
and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries
are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark
applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports
and which the failure to so would not reasonably expected to have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual
Property Rights</U>&rdquo;). Except as disclosed in the SEC Reports, none of, and neither the Company nor any Subsidiary has received
a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is
expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Neither the Company nor
any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written
notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any
Person, except as would not reasonably be expected to have a Material Adverse Effect. To the knowledge of the Company, all such
Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual
Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality
and value of all of their intellectual properties, except where failure to do so would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as the Company believes are prudent and customary in the businesses in which the Company and the Subsidiaries are
engaged, including, but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any
reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain
similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transactions
With Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of the Company or
any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party
to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or
personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments
to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director,
or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case
in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses
incurred on behalf of the Company and (iii) other employee benefits and awards, including any equity award agreements under any
equity plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance in all material respects with any and all
applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable
rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date.
The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that:
(i) transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii)
access to assets is permitted only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect
to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to
ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules and forms. The Company&rsquo;s
certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries
as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation
Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the
certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation
Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined
in the Exchange Act) that have materially affected, or is reasonably likely to materially affect, the internal control over financial
reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Fees</U>. Except as set forth in the Prospectus Supplement and the engagement letter, dated as of March 3, 2015, entered into by
and between the Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">and the Placement
Agent, no brokerage or finder&rsquo;s fees or commissions are or will be payable by the Company or any Subsidiary to any broker,
financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions
contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to
any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection
with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares, will not
be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights</U>. Except as disclosed in the SEC Reports, no Person has any right to cause the Company or any Subsidiary to effect the
registration under the Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the
Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except for a deficiency letter dated February 2, 2015 received by the Company from The NASDAQ Stock Market LLC,
the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock
is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements
of such Trading Market. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or
another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or
such other established clearing corporation) in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render
inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents)
or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and
the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation
as a result of the Company&rsquo;s issuance of the Shares and the Purchasers&rsquo; ownership of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">their agents or
counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise
disclosed in the Registration Statement, Prospectus or the Prospectus Supplement. The Company understands and confirms that the
Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure
furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses
and the transactions contemplated hereby is true and correct and does not contain any untrue statement of a material fact or omit
to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they
were made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties
with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
of the Shares to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions
of any Trading Market on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the
Company of the proceeds from the sale of the Shares hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including
known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry
on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate
all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in
respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability
to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt).
The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation
under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. For the purposes of this
Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess of $50,000
(other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent
obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated
balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar
transactions in</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">the ordinary course
of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in
accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(bb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local
income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject,
(ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due
on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of
all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid
taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or
of any Subsidiary know of no basis for any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(cc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent
or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any
unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns
from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person
acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any
provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(dd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accountants</U>.
McGladrey LLP is the Company&rsquo;s accounting firm. To the knowledge and belief of the Company, such accounting firm (i) is a
registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with respect to the financial
statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Shares</U>. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions
contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company
(or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice
given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the
transactions contemplated thereby is merely incidental to the Purchasers&rsquo; purchase of the Shares. The Company further represents
to each Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other Transaction Documents has been based
solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ff)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acknowledgement
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Sections 3.2(f) and 4.13 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers
has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short,
securities of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Shares
for any specified term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without
limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement
transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and
counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or indirectly, presently
may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation
with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction. The Company further understands
and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the
Shares are outstanding, and (z) such hedging activities (if any) could reduce the value of the existing stockholders' equity interests
in the Company at and after the time that the hedging activities are being conducted.&nbsp; The Company acknowledges that such
aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(gg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulation
M Compliance</U>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of,
any of the Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company&rsquo;s placement agent in
connection with the placement of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(hh)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FDA</U>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the
failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge,
threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint,
or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received
any notice, warning letter or other communication from the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">FDA or any other
governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution
of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product,
(ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising
or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation
by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v)
enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi)
otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either
individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company
have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the
FDA.&nbsp; The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United
States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to
approving or clearing for marketing any product being developed or proposed to be developed by the Company.<U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent,
employee or Affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(jj)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the
meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(kk)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries is subject to the Bank Holding Company Act of 1956, as
amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal
Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries owns or controls, directly or indirectly, five percent (5%)
or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation
by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ll)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in material compliance
with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money
Laundering Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any Subsidiary with respect to the Money</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">Laundering Laws
is pending or, to the knowledge of the Company or any Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as
of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability
company or similar power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and performance by such Purchaser
of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate, partnership, limited liability
company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been
duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the
valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by
applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Understandings
or Arrangements</U>. Such Purchaser is acquiring the Shares as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Shares (this representation and warranty
not limiting such Purchaser&rsquo;s right to sell the Shares pursuant to the Registration Statement or otherwise in compliance
with applicable federal and state securities laws). Such Purchaser is acquiring the Shares hereunder in the ordinary course of
its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchaser
Status</U>. At the time such Purchaser was offered the Shares, it was, and as of the date hereof it is, and as of the Closing Date
it will be either: (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under
the Securities Act or (ii) a &ldquo;qualified institutional buyer&rdquo; as defined in Rule 144A(a) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Shares, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Shares and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, subject to the requirements of Regulation FD, (i)
the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company
concerning the terms and conditions of the offering of the Shares and the merits and risks of investing in the Shares; (ii) access
to information about the Company and its financial condition, results of operations, business, properties, management and prospects
sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company
possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with
respect to the investment.&nbsp; Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the
Placement Agent has provided such Purchaser with any information or advice with respect to the Shares nor is such information or
advice necessary or desired.&nbsp; Neither the Placement Agent nor any Affiliate has made or makes any representation as to the
Company or the quality of the Shares and the Placement Agent and any Affiliate may have acquired non-public information with respect
to the Company which such Purchaser agrees need not be provided to it.&nbsp; In connection with the issuance of the Shares to such
Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not,
nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that
such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting
forth the material pricing terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof.
Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio
managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment
decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the representation set forth
above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision
to purchase the Shares covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&rsquo;s
representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents
and Affliliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction
(including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability
of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">The Company acknowledges
and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right
to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">contained in any other Transaction
Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of
the transaction contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>ARTICLE IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESERVED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Furnishing
of Information</U>. Until one year from the Closing Date, the Company covenants to use its best efforts to timely file (or obtain
extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after
the date hereof pursuant to the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>RESERVED.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Laws Disclosure; Publicity</U>. The Company shall (a) by 9:00 a.m. (New York City time) on the Trading Day immediately following
the date hereof, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b) file a Current
Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission within the time required by the
Exchange Act (the &ldquo;<U>8-K Filing</U>&rdquo;). From and after the issuance of such press release, the Company represents to
the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by
the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection with
the transactions contemplated by the Transaction Documents. In addition, effective upon the 8-K Filing, the Company acknowledges
and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company,
any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one hand, and any
of the Purchaser or any of their Affiliates on the other hand, shall terminate. The Company and each Purchaser shall consult with
each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor
any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the
Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any
press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required
by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or
communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the
name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent
of such Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction Documents
with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company
shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any
Purchaser is an &ldquo;Acquiring Person&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">under any control share acquisition,
business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement
in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan
or arrangement, by virtue of receiving Shares under the Transaction Documents or under any other agreement between the Company
and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents
or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto such
Purchaser shall have entered into a written agreement with the Company regarding the confidentiality and use of such information.
To the extent that the Company delivers any material, non-public information to a Purchaser without such Purchaser&rsquo;s consent,
the Company hereby covenants and agrees that such purchaser shall not have any duty of confidentiality to Company, any of its Subsidiaries,
or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company, and of it Subsidiaries
or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public
information. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions
in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. Except as set forth in the Prospectus Supplement, the Company shall use the net proceeds from the sale of the
Shares hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s
debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices), (b) for
the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in
violation of FCPA or OFAC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a
Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within
the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;)
harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments,
amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser
Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or
agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the
Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not
an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless
such action is based upon a breach of such Purchaser Party&rsquo;s representations, warranties or covenants under the Transaction
Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">any violations by such Purchaser
Party of state or federal securities laws or any conduct by such Purchaser Party which constitutes fraud, gross negligence, willful
misconduct or malfeasance). If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought
pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right
to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party
shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses
of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically
authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and
to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue
between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for
the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party
under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written consent, which
shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability
is attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or agreements made by
such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.8
shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are
received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right
of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESERVED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
of Common Stock</U>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation of the
Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply
to list or quote all of the Shares on such Trading Market and promptly secure the listing of all of the Shares on such Trading
Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will
then include in such application all of the Shares, and will take such other action as is necessary to cause all of the Shares
to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary
to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s
reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility
of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including,
without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in
connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Equity Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
the date hereof until 30 days after the Closing Date, neither the Company nor any Subsidiary shall issue, enter into any agreement
to issue or announce</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">the issuance or
proposed issuance of any shares of Common Stock or Common Stock Equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration
is also offered to all of the parties to such Transaction Document. For clarification purposes, this provision constitutes a separate
right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to
treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect
to the purchase, disposition or voting of Shares or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither
it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending
at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section 4.4.<FONT STYLE="color: windowtext">&nbsp; </FONT>Each Purchaser, severally and not jointly with the other
Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company
pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence
and terms of this transaction.&nbsp; N<FONT STYLE="color: windowtext">otwithstanding the foregoing and notwithstanding anything
contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation,
warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that
the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company
in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are
first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any
duty of confidentiality or duty not to trade in the securities of the Company to the Company or its Subsidiaries after the issuance
of the initial press release as described in Section 4.4.&nbsp; </FONT>Notwithstanding the foregoing, in the case of a Purchaser
that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing
other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion of assets
managed by the portfolio manager that made the investment decision to purchase the Shares covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>ARTICLE V.</B><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.&nbsp;
This Agreement may be terminated by any Purchaser, or by the Company with respect to any Purchaser, as to such Purchaser&rsquo;s
obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by
written notice to the other parties, if the Closing has not been consummated on or before March 11, 2015; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent
fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company),
stamp taxes and other taxes and duties levied in connection with the delivery of any Shares to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement,
contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
via facsimile or email attachment at the facsimile number or email address as set forth on the signature pages attached hereto
at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such
notice or communication is delivered via facsimile or email attachment at the facsimile number or email address as set forth on
the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading
Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight
courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices
and communications shall be as set forth on the signature pages attached hereto. To the extent that any notice provided pursuant
to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
in the case of an amendment, by the Company and the Purchasers who purchased at least a majority in interest of the Shares then
outstanding or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought; <U>provided</U>,
that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the
consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">waiver of any default with
respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or
a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or
omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment
or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the
comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser,
Any amendment effected in accordance with accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Shares
and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to
whom such Purchaser assigns or transfers any Shares, provided that such transferee agrees in writing to be bound, with respect
to the transferred Shares, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties of
the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended
for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor
may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect
to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action
or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding
is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and
agrees that such service shall constitute good and sufficient service of process and notice</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall
commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of
the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party
for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo;
signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESERVED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement
of Shares</U>. If any certificate or instrument evidencing any Shares is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu
of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the
Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of
the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the
Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation
the defense that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person
under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived
and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate
legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each
Purchaser and its respective counsel have chosen to communicate with the Company through EGS. EGS does not represent any of the
Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms and Transaction
Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It
is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between
the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the
Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays, etc.</U> If the last or appointed day for the taking of
any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken
or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after
the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>WAIVER
OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the
date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td colspan="2" style="layout-grid-mode: line"><font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>cyclacel pharmaceuticals, inc.</b></font></td>
    <TD>&nbsp;</TD>
    <TD STYLE="text-decoration: underline; layout-grid-mode: line"><u>Address for Notice:</u></td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="layout-grid-mode: line">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 4%; layout-grid-mode: line">By:</td>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; layout-grid-mode: line">&nbsp;</td>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 42%; layout-grid-mode: line">Fax:</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">&nbsp;</td>
    <TD STYLE="layout-grid-mode: line">Name:</td>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">&nbsp;</td>
    <TD STYLE="layout-grid-mode: line">Title:</td>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="layout-grid-mode: line">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="layout-grid-mode: line">With a copy to (which shall not constitute notice):</td>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="layout-grid-mode: line">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</td>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="layout-grid-mode: line">Attn: Joel I. Papernik, Esq.</td>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="layout-grid-mode: line">666 Third Avenue</td>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="layout-grid-mode: line">New York, NY 10017</td>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="layout-grid-mode: line">Tel: 212-935-3000</td>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="layout-grid-mode: line">Fax: 212-983-3115</td>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[PURCHASER SIGNATURE PAGES TO CYCC SECURITIES
PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of
the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name of Purchaser: ________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Signature of Authorized Signatory of Purchaser</I>:
_________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name of Authorized Signatory: _______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Title of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Email Address of Authorized Signatory:_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Facsimile Number of Authorized Signatory: __________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Address for Delivery of Shares to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">EIN Number: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&uml;</FONT>
Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed
to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations
of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded,
(ii) the Closing shall occur on the third (3<SUP>rd</SUP>) Trading Day following the date of this Agreement and (iii) any condition
to Closing contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company
or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be
a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such
agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>t1500497_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><img src="ex99-1logo1.jpg"></FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: right; padding-right: 0.25in; vertical-align: middle"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cyclacel Pharmaceuticals, Inc.</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="ex99-1logo2.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>CYCLACEL PHARMACEUTICALS
ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Berkeley Heights, NJ, March 3, 2015 </B>-
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &quot;Cyclacel&quot; or the &quot;Company&quot;), a biopharmaceutical
company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious
disorders, today announced that it intends to offer shares of common stock in a public offering. H.C. Wainwright &amp; Co., LLC
will serve as the sole book runner for the offering. While the offering is expected to price before 9:30 am EST on March 4, 2015,
the offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed,
or as to the actual size or terms of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The offering will be made in the United States
only by means of a prospectus supplement and an accompanying prospectus filed as part of an effective &ldquo;shelf&rdquo; registration
statement filed with the Securities and Exchange Commission on Form S-3 (File No. 333-187801), which was declared effective by
the United States Securities and Exchange Commission, or the SEC, on April 22, 2013. Copies of the prospectus supplement and accompanying
prospectus, when available, can be obtained by request at H.C. Wainwright &amp; Co., LLC by contacting by telephone at (212) 356-0530
or by e-mail at placements@hcwco.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Before investing in the offering, you should
read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Cyclacel has filed
with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus, which provide more
information about Cyclacel and the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This press release shall not constitute an
offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction
in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws
of any such state or jurisdiction. Additional information can be found in the Company&rsquo;s filings with the SEC available at
www.sec.gov and on the Company's website at <U>www.cyclacel.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cyclacel is a biopharmaceutical company developing
oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine,
Cyclacel's most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial, which has completed enrollment and is
being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other studies
for myelodysplastic syndromes (MDS) and chronic lymphocytic leukemia (CLL).&nbsp;Cyclacel&rsquo;s pipeline includes an oral regimen
of seliciclib in combination with sapacitabine in a Phase 1 study of patients with Homologous Recombination (HR) repair-deficient
breast, ovarian and pancreatic cancers, including gBRCA positive tumors, and CYC065, a novel CDK 2/9 inhibitor, with potential
utility in both hematological malignancies and solid tumors. Cyclacel's strategy is to build a diversified biopharmaceutical business
focused in hematology and oncology based on a development pipeline of novel drug candidates. Please visit <U>www.cyclacel.com</U>
for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.45pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 8pt Wingdings">&thorn;</FONT></TD><TD><FONT STYLE="font: 8pt Times New Roman, Times, Serif">200
                                         Connell Drive, Suite 1500, Berkeley Heights, NJ&nbsp; 07922 USA T: +1 (908) 517 7330
                                         F: +1 (866) 271 3466</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.15pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 8pt Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Dundee
                                         Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382
                                         206 067</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 8pt"><U>www.cyclacel.com
</U>&ndash; <U>info@cyclacel.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This news release contains certain forward-looking
statements that involve risks and uncertainties that could cause actual results to be materially different from historical results
or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements
regarding, among other things, statements regarding the proposed public offering, the efficacy, safety and intended utilization
of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future
research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially
include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety
and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval
to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the
risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product
candidates. You are urged to consider statements that include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot;
&quot;should,&quot; &quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot; &quot;expects,&quot;
&quot;plans,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot; &quot;designed,&quot;
&quot;goal,&quot; or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list
and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and
other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking
statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Contacts for Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Company: Paul McBarron, (908) 517-7330, <U>pmcbarron@cyclacel.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investor Relations: Russo Partners LLC, Robert
Flamm, (212) 845-4226, <U>robert.flamm@russopartnersllc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&copy; Copyright 2015 Cyclacel Pharmaceuticals,
Inc. All Rights Reserved. The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>t1500497_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 60%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><img src="ex99-2logo1.jpg"></FONT></TD>
    <TD STYLE="width: 40%; font-size: 10pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cyclacel Pharmaceuticals, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><img src="ex99-2logo2.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>CYCLACEL PHARMACEUTICALS
ANNOUNCES PRICING OF </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>PUBLIC OFFERING
OF COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Berkeley Heights, NJ, March 4, 2015 </B>-
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &ldquo;Cyclacel&rdquo; or the &ldquo;Company&rdquo;), today announced
that it has priced its previously announced public offering of 10,000,000 shares of its common stock, at a price to the public
of $1.00 per share, for gross proceeds of $10.0 million. The offering is expected to close on March 9, 2015, subject to customary
closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The net proceeds, after deducting placement
agent fees and expenses and other estimated fees and expenses payable by the Company, are approximately $9.2 million. The Company
intends to use the proceeds from this offering for the continued clinical development of its most advanced product candidate, sapacitabine,
in myelodysplastic syndromes (MDS) and other indications, Phase 1 clinical trials of its cyclin dependent kinase (CDK) inhibitor,
CYC065, and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">H.C. Wainwright &amp; Co., LLC is acting as
the sole book runner for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The securities described above are being offered
by Cyclacel pursuant to a &ldquo;shelf&rdquo; registration statement on Form S-3 (File No. 333-187801) filed with the Securities
and Exchange Commission, or the SEC, which was declared effective by the SEC on April 22, 2013. Copies of the final prospectus
supplement dated March 3, 2015 and accompanying prospectus relating to the offering will be filed with the SEC and, when available,
can be obtained by request at H.C. Wainwright &amp; Co., LLC by contacting by telephone at (212) 356-0530 or by e-mail at placements@hcwco.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This press release shall not constitute an
offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction
in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws
of any such state or jurisdiction. Additional information can be found in the Company&rsquo;s filings with the SEC available at
www.sec.gov and on the Company&rsquo;s website at <U>www.cyclacel.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cyclacel is a biopharmaceutical company developing
oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine,
Cyclacel&rsquo;s most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial, which has completed enrollment and is
being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other studies
for myelodysplastic syndromes (MDS) and chronic lymphocytic leukemia (CLL).&nbsp;Cyclacel&rsquo;s pipeline includes an oral regimen
of seliciclib in combination with sapacitabine in a Phase 1 study of patients with Homologous Recombination (HR) repair-deficient
breast, ovarian and pancreatic cancers, including gBRCA positive tumors, and CYC065, a novel CDK 2/9 inhibitor, with potential
utility in both hematological malignancies and solid tumors. Cyclacel&rsquo;s strategy is to build a diversified biopharmaceutical business
focused in hematology and oncology based on a development pipeline of novel drug candidates. Please visit <U>www.cyclacel.com</U>
for additional information.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.45pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 8pt Wingdings">&thorn;</FONT></TD><TD><FONT STYLE="font: 8pt Times New Roman, Times, Serif">200 Connell Drive, Suite 1500, Berkeley Heights, NJ&nbsp; 07922 USA
T: +1 (908) 517 7330 F: +1 (866) 271 3466</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.15pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 8pt Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Dundee
Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 8pt"><U>www.cyclacel.com</U> &ndash; <U>info@cyclacel.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This news release contains certain forward-looking
statements that involve risks and uncertainties that could cause actual results to be materially different from historical results
or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements
regarding, among other things, statements regarding the proposed public offering and the intended use of proceeds, the efficacy,
safety and intended utilization of Cyclacel&rsquo;s product candidates, the conduct and results of future clinical trials, plans regarding
regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual
results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials
do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel
may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital
requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization
of product candidates. You are urged to consider statements that include the words &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo;
&ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;projects,&rdquo; &ldquo;potential,&rdquo;
&ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo; &ldquo;continues,&rdquo; &ldquo;forecast,&rdquo;
&ldquo;designed,&rdquo; &ldquo;goal,&rdquo; or the negative of those words or other comparable words to be uncertain and forward-looking.
For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report
on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov.
Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Contacts for Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Company: Paul McBarron, (908) 517-7330, <U>pmcbarron@cyclacel.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investor Relations: Russo Partners LLC, Robert
Flamm, (212) 845-4226, <U>robert.flamm@russopartnersllc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&copy; Copyright 2015 Cyclacel Pharmaceuticals,
Inc. All Rights Reserved. The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex1-1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1-1logo.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0.E:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C8M8S`Q-"`W.2XQ-38W.3<L(#(P,30O,#@O,C`M
M,#DZ-3,Z,#(@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z,$(S.$$W0SE#,C$T,3%%-#E$.$8Y1$(W,35"
M-D,V0S@B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z,$(S.$$W0SA#,C$T
M,3%%-#E$.$8Y1$(W,35"-D,V0S@B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HY.#$R-#@Q8RUA.6,X+30R9F4M8C1E."UA
M,#@U,C%A.&9F9C<B('-T4F5F.F1O8W5M96YT240](G5U:60Z-&0T-F9A,F4M
M86)D-BTT-3ED+3DT,3`M86$W,3=D.&$W8SEE(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YG97)M86YR97EN;W-O/"]R9&8Z;&D^(#PO<F1F
M.E-E<3X@/"]D8SIC<F5A=&]R/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z
M4D1&/B`\+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_M`$A0:&]T
M;W-H;W`@,RXP`#A"24T$!```````#QP!6@`#&R5''`(```(``@`X0DE-!"4`
M`````!#\X1^)R+?)>"\T8C0'6'?K_^X`#D%D;V)E`&3``````?_;`(0``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("
M`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`%P%?
M`P$1``(1`0,1`?_$`*\```(#``(#`0````````````@)!@<*`@,!!`4+`0`#
M`0`#`0$````````````%!@<$`@,(`0`0```&`0,#`P,"`@<)``````$"`P0%
M!@<`$0@A$@DQ(A-!4105%V$6<8&Q,B,E&*%R,R0TM&@Y"A$``0,"!0(#!@,%
M!P,%`0```0(#!!$%`"$Q$@9!42(3!V%Q@9&A%+$R%=%"4B,S\,'A8G*R-/&2
M)(*BPE,E%O_:``P#`0`"$0,1`#\`Z^3V4>0UDSAS;5H?/+,5`R!CWD[D:N4?
M"@9)G(J%DZPSL3H6[.LMD'A2D500`0(GN&XZ]&6=N"BWV]/D;B1F:#_-CQ3>
M[Q=KG>I[[<_;/1^5(-!3PC3;3"YL>\H/(+D.[A4U.6O(2M(1S]!&Y3\WDJTH
M1]0CEW9$5WLL91X8S4J?>(D#H)OL(:<9$*TML/$,C>LCH,L)L7D'*I4P1+A,
M*4U0"3EE7V#&A/Q"Y9R4Y\A-HQ(OR\RMR7H<+CD5UY"XVV8G:^,X9,AW`1"+
MYP=%1)$QQ`#=O4`WU.>>1;=&X[Y@9(5[O?[<6[TON<IWE;UNC3PY1L$@Y_PU
MI5.-=$K&HS,:]BW2CI-N\;';K'9NEV3HI%"B43(N6YTUD3A]!*(:AJ5;"%]E
M`_4''I&4V76E`=U:?Z<)P\2MFR'=Y?ER[R#D.[7K^1N05KH=23L4^^E6D/6(
M=VH@QCD$UC"B(H)I![@]W3KOJ@<W0AM$,MI2D*9J:`#,I2<2WTU1]V[<O.6H
MJ:FK`J3U6O\`9B4^8VQWVA\<*U=\:Y`NV.[<AD^FU[]6JLV^CBN(>:D2I2#)
M\V072;+D7(38IC``@.LW`T>9<7&UI"D>63F`>F"?J<\F+;&E(44DN)&1IUPS
M;%;(6>.:,D=Y)2"QZO!N7;Z6>JOI!VZ<1J"SITZ<*'4%59=901'80`-])$[*
MX/J.E3^)P[P05V]A(UH/?TP&?+7D;<(S*N*^)V%'R<=EW,1U)"2M"R9'/[>T
M)F)S2%G18J@*3IVL=$R"13^AAW^VF'C]FCIM[MWFFK:-!W.9_NPH\IOCZ[DS
MQR"/YSPJ5#44H-?C@A8GCG`-XANWG+CDB=F?QB%DYTUYGV*D@^`FR[LK)F\1
M9M2JJ=?C(F!`#IH8]=WV&E(92GR2H&E!6E1UPR1[(RRA*7UDKVT.9ZUP..#V
M7*K%/)VWXOR-9W>3N/4[!$GL7W6522+88*3%0PNZG++I=QGB#!$H?"JH(&,&
MP_71J8+1<+$)#24IF"E::GOIK49X`6]%[MM_,4`JL9_*HYTK_;OBN?+1'98K
M>`F>=\.7NZ526PS9H2RWB)K,R]CF5IQPV>I'LK*00;'`IU$6Y>XAP#NV$0WV
MUW<)E1_U%45S:6UM*`KWUZ^P8'>IL20Q;47:.5;VG4Y`G\O_`%Q27D!M]\6X
MN80YK8$R3D&+@8!WCJXY.@H"URHQ%CQ:_1:GL",@BFX$#.V/R^]3<3")1WUH
ML\<,S)5B>2*K*MI(SS!T^FF!W)7ON+3`Y0TI6Q.PK`)I2J2:_"N"1XLV%[GS
MD-D/.E2R'<)##D=4JM"U>OJV&0>TV7FI:':2KR:8(J.#)*G9%4%%4`]%-_36
M:\C])M@LRTI\U1UH*]>OQ&"_%WW;M<GKW'),):$@9Y9`#\1COX^HVC(_,WD3
MD)C?;NKBW'3MKCIC17<](+5=>Y`V3>/Y^,8G4%O^.1L8$A*`B4#;:XSGA"LK
M,"B=[B0HD@5]WTQHLJ1.Y?-O#:B6"@)URJ/9IUP)O.;E]F_&/*'#&0J%(K_Z
M4\17AG1\\F9.546\A<K8Y+#M(Z7*F8""WB@<@<!'V@?UT9L-HM;ELDQI12;@
MY'44#VD52!\:?'"AR_E-XM_(H[\9)-L2X$+/0`D!1^AP]AD];R#)I(,U"KM'
MS9L\;*)'*=-5!<A%$5"&[NTQ!(8!`0'8=]39Y@QT*9/YDFA^>++'E(DQFY"/
MR+37YC"5F$S>TO,,[Q=^YN03XK-B$UV_;T]IEA@0M'QD.5X9$KD0^$G?T0_X
M8!MJDR@VO@"7MJ?-#FVM,Z`IZXD[+[B/5+R"H^68Z2!7+/S.F)EY7;=G+`-,
MQCR&XZ3=KD,A0F3ZU"R6+D9)VO7\CUMX"QI*%"),)TT'R39`QR')U,(^FA/"
MHD:X378DL#R5QS4GIFG,=CC;ZH3)UIM[%VM]3*9DA24CJ0%94Z@UP;O$KE1C
M_E]AV%RG1'!T%5C*15QJSE0J<U3+6S*",S7Y9KWE<M7#5X0X)B8`,8FPZ$\C
MXZ[9II@R?$P<T*'45R^6A_9ANXWR*+RF$U,B&A2FCB>H-/\`$8&JNU6PPOD9
MM-:')60GV/9'C^2Z-Z$^M4NXAHZS.K`:+<R+=$SD`)WM!,!";;%'K]-;Y#OG
M\00^XD!R,\H`@9E-?#7OIA99M6SGBV@M184T%:FFAQ0W%>7O5(YW\L.(^:,F
M7RV15EK\?D7":L[:9856='EUEDGL)".!=`H1['&*(B)#"8I"[:,WQ*)W&85X
MCI2%)("J#MN&=/A@+8WW&^;SK%+4H-*3X#4YY).7UP+\/E_)N%LB<W>)&6<N
M9+EKW/S55<<;;`M9)<TU'0U]=F8UXT.LBX*95.N+JE,X'M-N4/=H^^Q'N$2'
M?6$H"(R/Y@`&>68/MKWPO0;I(LUPG<7>*BN8LA!)-14D9=?EADG)QO9L/<((
M7';S(UT#+TZSJN-ZUD*/GY!.R.\GS:J#9I-J2*:@KJ)_G`8PE$!*!0VVTD6Q
M]$GD)G43Y.XFE,J5RRP^W^&Y:N&HLS9493I&=3NSK7/7K@1/(BURWQZXX\.U
M8;+V2H[(2V9L58TR-8&EQE_RK:SL11_F=-\8'7;NZ<$'M$@%$H:9>*NQ;A>)
MR%A)8<02,AE3M\L!>:M2[39[>B.LA]U:$$U/58K]#B>^0EEEWB1BFF<H,`97
MO+0U'M-/_GW&MDGGUIA<B0DXZ:,GC--.6<.5&SH#+]P?%L(]1^FA7&DP;O,E
MV64`$("EA7:A-!W_`.F._F=OG\>L[=^M"U"0PI(4DDG=49TK4=#VUPT:ZJJV
MW!,[,J.)2&=R>-U[*BO$R+B-D(Y\>N'EFY4'S,Z+A,&C@P!L'J`==*C(0BY!
M#>;8?H/=6GUQ0IKZI-@,@@I6N*%$:$$I!PM[Q(Y$M<QPZGLO9ER/;+W,1UFN
MZDW8[9-O)#\&NUMPZ5*@W1<K'2229LD3=1]PB'KIKYI$2]?&X;*4IWI32@IF
M5$=,(_IA,0QQI^9,6?+;6HDDDZ)!IGBSN+-WR%S;&T9TGK'-U+!BEAF*YBJC
M5U\YB5[%%PK@4$;S*3+51!YW28CNDD4>T"AH9=0CCSR8"`DR%)%214Y@'Y8[
M>.2IG+%3)#Q*;<72$4J,A494^N)IR5XSY;_;V;G^*F8\@T+,$&W5E8-O,V)_
M;ZW:7+4073KLQ'6!VLD@TD!`2_(380,(:XVN]17WOL[DE!8&5:4IEK[?[L;>
M0V%Z'"<F\?4LS2L$@J)_A&6M,L79B9QD"_\`&V$',J,A!9(<51TC<PB7*\,X
M)/L&RI%W4>JS43,BB+E/N+M[1V^VA\],=J[M+AD&.'4$=M=,'[<]/5QVMT&V
M9]NJOP3K@$/#A;<@Y!PGDJVY-R%<\A6!MF*YUAG(6>:>2I6D!#23EO&-&Q5#
M&1`&Z28%[B^HAU#?KIL]1-D>8RVPA*4>4#0`#/+]N>$_TL<+]HF%Y9/_`))U
M)/RKCYOF`LN0Z+5^.MBQMDJ\X\E9_-M;I]@4K,](L6DQ6Y%4IG<<]9H+D;]Y
MRB/:H`=_\-=?`RA:Y1=0E0$<G,`T.U1^=<<O4S:A,'RUE*S)2,B17Q(P:6<>
M/M]R]^RD;5,OW3&M,J"R[^[EK<Y(M)^WM7$2F@Q8.)!-8JYDT76ZIQ,.XC_1
MH';[NW"D/N%`4M14!D.^&&[6EVZ1XT9*BE%$5()'[M,*TY+8[R=C+G!PPP96
MN3.;$:-FA"]FNC16V2;ERX&!:@JQ*@NLX,<@F/\`80#IIPX_/;789\A;2"I(
M)%0.R<P:9:XF/)H+MEY79;0TXLI=2L',Y^%WV^S#/,?\4[EC?+U5R#&YYR79
MJJPAI.*LE&MT_(2D7+N7A=F<HFBLLHBDY8CU#8`W'2"B^I?M:H:D"O0T%<L4
MR!QE-KGHGMK4I9`!!)I\B<4]RTY%/<:\J^,6(;I8'=,PMF=.=BI&PL'RD4J_
MOJ9RIP-<7ED7#=5FA(@8P"(&ZCM_46LEI>FVI]Z*D*E,I*SU.VHR^:A@3RJ^
ML6GD,*VSR4P)#N1!/YMJJ`_`$X([#F'\H8OR5D1Y(Y2EKUB*S?BOJ56+$Y5?
M2='<D*4%XQM)N#JN'L>H?<Q1.81#^O065-CW",EPBDUJH(`I737!V#;I5JNC
M[[!*X#R:@DUI^;O@J#&W3V*/O,38H#O_`$;&`?H(_P"S0AM14@!P4W$_6N&9
M&Q+J2Z?"1^RN%B53+E\YB<BLETC'UKE*3@#C[.!4;G,0"QFL[D'("8%_6*TC
M)(F!5A$1)1ZJ)#WF_L>'837'H2"^A*ICHRJ/RCI2NE.O<XG8N,OD]\>C0%TM
MT?)1_B]F77/!,WKC:>3J4NSQQDG)%%NY6;D*S:%+I/S:49)BEV(.'<9)/5FC
MY`QDR@<IR_W!Z==`X=R#3Y4^A*VSJ"!G_A[,,,VRLN1]MK*FY8_>)/UU_#`U
M8GY*YMPSPTNF1^7[!LOE3&EBM%5;E8D3:&R*9B__`!*@[9I)@5,KJP`<HB!0
MV``'1F38X<B\HA1%`LJ0%J(T34`Y?.E,`8G(+K!XPY+Y`D(N0<4A`_BHHA)Z
M:@5Q=6(,5WG)=&C[QG2ZVQ><NK1G9&%7K,])5B+I<9*-2O6L&4T.NU6D';1)
M<"J**F,'<'0-]QT/N5S3;5JAV]((22%&@))TZ],;[5:5W:U(D7-2@MT5(!(H
M,B/=UP$_+:P9^\>L[6N2-)O%ORCQ8;S$5`YHQ7<'ZL[)TF(F7R+%*[U^=>&6
ME5BM5W(%40,<2@&WTT6LD>'RQO\`3Y5&Y)2:'2HT.G8ZC"QR=VX<*=;NL,J7
M9T?FJ2=!UK[*YUPVU')%6<8T'*R,@DI32TM>\#*D4`Q`K[:&5FW+HQP]H`DS
M1$1'TZ:53;G&YIM:LG-X1_W$)'XXI0N+3EN%T3_2#97\AN/X8_-7YF83RIDC
MGSS&LE*AI)*OPG*/)))&X%4%JRKSA*RN%Q=+''M$YD-M]P'81Z:]3V6YLV_C
M,)Y3:7'4)`H-36O?'@Z[6R=*Y1,>@C;M/YJ&G3+OUQ[.0K+"YTI[S$.'Y-!3
M*T`JB:XOTB)L_P!^5F*16W:P<$(05)*.$`#X3#VJ;;ZV%^<RXN;*4V(\@@I3
MM55%,_$:T-:TR[8^S%)N:6K=&9'ZH@`N.:!7:@K49@_/#'?_`)WJ)<,<\[K%
M6;O"/JW/M*!('4BY0"_E))E4'WJ`F(E`IA'H`#Z:4?5"ZM+XV&FB@UI50!IH
M<._HS!D0^:.-J8*9!33<2*#--<JU.-WO4!.;[AMT_AU_LUYQU`'M&/9!24,K
MW'N?I_AC-YXR,2Y2R!;N<$C3<_6S&46ERHOZ/Z%#1$4\:'5"15`71C.B"8%C
M;#OMZ[ZJ7+94:.B']PWYE8Z::9>%/?$)X1;+B_+N+L*0EI/WBE$$*-=RUD:=
MNN)%Y9L,Y7IG&NKS-KY$V_(,6EFF@IK5^6AHEFT<"O)E^`QU6A`5'X!`1Z_?
MIKYP&Y01<7$A@U+9SJ.QQW>JMLN+%H:D/OI4$NHRH?XM=</KQV;;'U)'82"%
M1KYC%.`@9,`B6VXB7K[NGIJ87+:J8\UN`7NU^)Q8+00N''<;\3:P*'36G?"5
MY"?"L^=Z*;W%PFBG<^+ZL5CT[@>Y(ZC=ZHZ<$8B;V%=>TW?V^[8=4;[54GT[
MK#3N=;6"H@@9#?7(YG$@<N!B>L#,*X)*/,95Y=<PO-O2FE*TSP]PH@)=M@'<
MH[;]-PZ[B/VWU,'%$K#5<J>+]F+>I(4\H.Z]!CI`2=Y#]J(F(42@`FZE$H;G
M^/?^\)2=>GTUS11#>UH*+'>N7RQ^27OZ1H&_X>OSTQ#LB4J%R31K=CZR-BNX
M&Z0$K791`0Z&8RS0[4^Y3;AW@4X"&_VUW19'V<EIZ.-%@D_CC%=(Z)L)R'*`
M#3@V@:YZU/Q&$*<2+NA6.%/-3AIEN/&8GN.;J^4IK`/##^98*C;C/E:2V:ME
MC"*Q_P`<R14BI@(!L&VJCR"*&[W`OT,[HJU-[J=!N!))[4.(]8)K*^.W7C-P
M(\]GS$-@Y%=4E*2@'_,!KCI\6>=?V*\?F8,7VVO.(._<7I&5B96N'`R4VHA>
M5#.*G\B)A%<RZ*$BD01Z]"!Z;:ZN9V]F;?(\EAS=&<`JH`[4T%<\NM?ICI]-
M[L]!XX]:RG;*C*55)(JJJE4IGT&&7XX12XD<,UK+9G`.K6-=D+1,RJ27ROYF
MW6L5EX0KD0#Y%UD5Y%!`1-N(`32<5&\7U,9/_&:<":G3:,R::T.'J&H<>XT'
MG$$37033J2K(9X7/9J)R7R)POR;AZU<973FYY7935SLD^DN4YWEX67-)0DHD
MC\NQ7"!DD%"_7<!#ZZ>T-V2/RIB2)"/MDE(--,B*],*"X][N7$)MN7$<5/="
MUH7N2`*A5*@FI(KTP=_BISG)YIX=T1M:B+-\C8E4=XDR1'NS&_.9VRGG*S=$
M<@J/R$'XQ*`;^NW32)S2)]A<G'&/YK#RJI*<A]>W]^&[@-T-TL#<=:%-RXQV
M*22":BN>6!I:_P#N]<A_X^#_`-JW^H:85*6GT_2AP&JI"J>X;,*:FG#ZO)4!
MX1#0#[QYN"_YYK%23XP"<H"4>3F/`'NV$HE$7@#W!]2[#U#[:`<:?+:9BT@[
MA$4,M:U3AVYB6U*M[;Z?Y*IR`3J`**U`S/PP`W*?'=_\;G(9]SNP%#O9OCKD
M&12+RVQ+"H_($2#Q8B*F4H"):D+_`,PR)[U@3*`[;[Z:K/+9Y1`5:+H3]^A/
M\M9/1-*=ZGO[\)5V@3>#7AKD%D05\<<-'F4Y*J:BH)HF@JDZ$Y8+O$V1:AF+
MG1$Y2Q].,K'3+GQ'AI:#E63A)8BS=S:2.`16(F8QV[A,%=CD/[BF`0'TT&NL
M.3;;!^FRD%*R\O/H17(CV4PRVJ<U=^7.3X2@8IC-$&HR)224D:U!R/2NF*)\
MI,3(8,RWQ0YVUV/,)<19#;TC)RS8IA,^H=Y43BDP>"F(&.BQ>.1,'=N!`#IK
M9PZ<S)L\SC<E)*U));-1D?"3EKWT[X%>H$63;[K"Y+;VR4,N`O*!`JFBD_B4
MX%3R/7B`JW/CB5R<K%23G:YAQ:FL<Q6\A/R(C^6\HN4V=776.41;N5HM58#^
M[<4N@]-&>,-K?XO<;:I83*-=B2#44_;A1YU(9B\IM%_8:4["!3O6E0I4D:^Z
MN&D7;X.07,>@5-DX2F<>X*K@W:Y1JABJQ[FVV1LW>4610$/[ZC-(IC`8HCL.
MDIA+MMMWF.I/FN;D@Z$%)VG772HQ3ER6KQR!I"1NBMM)5W!W!*OF*T/MP*GG
M51E'&`^/",(Y19S"W+/$Q(YRX,)447AEW0(F.8I3#MW;?3J.BWIZXENXR'7/
M&A#:J@9$^$C+IE6OPPN^KH4NR1-M4K^Y1M/8A:2*^\BF*^Y$W3*V.^3/&"A\
MRW\+8>)60UX^.@9F,0`(UIEUNV2+"1]Q54(F4L<Y.;N3,?IW?QWT1MT6-<(\
MV19T[9J-VXDC3Q9"@KTP*OERN#5^ML/DQ"K.^A)\((`5X,U5K77.F'<9"_&1
MQ;>$&A"$:$H5F3;%1$HHD;D@'Q42I=O04P3(';MTVTA0D$2FZ:^:/QS^N*S<
M74.V!^0"-H85D.W3Z4PASA,QG9+PX\BF5;[_`-9<1>;RM`3`14.`%?F73(!?
M<)SMP.`;=>O35'Y`E+?-8B'J4*4TS%*DFGUQ%>-^=+],+@J(%%P[C0:T"03]
M,,`\1%GKME\>?&Q6M*(JDB:2E"RP)G(8R<W&KK)2"2W:.R:Y%=@,4WN`0ZZ4
M.:,2(W)E?>"B%-C:=10A/:N'OTNDL2>'1S&(!0I0<KJ#N56N+JYQ7W(^(.-.
M5\P8NE&;&T8PJ4K=&\?(HD.PFPB4?F&.>&$IC)E4*`@'H&^L7&X<29-;CRP5
M%RM%#+,`G,:Z#!3F<Z19.//W.$K8MM2:C6M5)&5/?CGQ"R9=<S\2,;95R(=H
M>WY`H(VB438D*#-H>39K*$:-MMMTT"AMU]=?;_&9A7=$:/\`TDO('U^&-%EF
M2+MQ5NXR:*<=BJ.66J!K7KA/?B2PMEF[X5RU+5/D3;L=PZF>,B$;UN&AXITR
M;F+//S**%4=%%3O5^NW3II\YQ<8+$UD265.'RAU'8=\3/TT@W*5:9Z(S@;)D
MG6IZ^PX\^5'#V4Z+7>,DK;^0%KR5&GY"U)((29B(QBU!85T_C<?(S*!S&(4=
MNO7?7+A4^#(<E^0RI"3%/4?PK[8R>H]JNT!R`_*DH<09:<@%5_.CN3C1C&!_
MEK#?T_!9]/K_`-,G]=2B2H+D+0@44'%'ZG%YC$?9,KZAM)_]HPE_FRF(^4?Q
MJF#8/\'*([;?7\(1^^J)QEU!XG<4%)J4'/X)Q)^8J2?4&S..YEI)T_S!T?2N
M'4+KF0175*3N%$BBHDW#<P)D,<-O][;^G4Y90@);%,E`"O;37%8==#"7%)!<
M6$E6T9'J>N6$K0."\:^4S!V5[)E23=GMJ>1+?6*&]8NU4'&&IZCRSIC"3$$B
MF<"MWBBB)5CF.'<<HB&G]4Z9Q&6TA!"XBT561D%H-/"*]0:&NF6);&MD?GL5
MZ7.4"^V\0UU+:P#0J^%1EWQ6N!>5F;(F(R%X_>3]_=X<Y4XZK\B?$F;#-6HQ
M&9JG",W!H:5CWDD!6#N:.@@BF[3(/R'$.FYO4C,LUI,EF_VU*784@C>R/S(K
M3,FFTTKI[\8+3?;U"BR^-798:D,I(0^K)*J5H*5W=,C[0,,BX9R&8[!Q%ITW
MF&R.[/E6;KU@7EY)TS)'KC(IN)!FS*B@F0@)@*2!#EZ;#W=.FE&\(C-WE##*
M`AM"TD^XFN?NJ!B@6$S#QMM-R/FSE!>TI_>!)VT)KJ*'7`$^#2=)^VG*NJS1
MRI9`@.5V2U[='.3@$BD21=@K'O7('$5CIKH%V*8=@TQ^HR7#<(S[*2J*ID`$
M9`&JJYG7W#$]]%G5_97&++4!<TSE$M_O)1L;"23H0373MAYI5>[?8HCL(`&_
MH.X=1*.WH&IVI=`?+&Y0Z:?CEBV47U`'Q&$]^:9V]A>*E2M#<BA8>H9^Q98[
M8HD05")UZ/F#'D1<]GJW%,P`??IL/73WZ>-QY5YD(DKVJ#/AJ#KX<L2KU4=?
M_1(TM:#M2_F010#Q`5PU>B3<?8:74IJ).@M%3-5@96-.W$HHG9/XQ!PW%$Q/
M9\0HG+V_3Z:3IB/(F.I)/F)<5NR.?;#]:WDS+0R^T`8RFDT((S]V!6\AC2OO
M>&?(-I93)%B%Z"^2<E<%(=(#F40!J40.'8<QG?8!0WW$PAMHUQ;SG+LT6LB2
M:5(&@P"Y[':=X:_'D42PI)%3G2H/;^[%%XTK%G9^(V9J,FFY+93\.LI12*1S
M+"]%5_C>TI1)`$X`M\QB+)]NP;A]/IK3<)D=?-$2T@B/]PT:?Z5)KGIT.,UK
M;=5P)UDD^:F(\-#_`/6JF5*]1C*MR>K^<H[D+SLB*/*4!_2;7G+*GZM+FF`6
M-63.[*\5<*2JK1R9K'2S40[!(N)#%`>H:M%@0E=FC2'542`*).ORQY7OL7DS
M-SN$>TNH6V3FH4(`\-?$%?CA8N&\+6*IY3J=EQ[E+$=EO$7+"XA8&.O$#*R<
M@\`.U1!*.BI9=\Z4,/<(@FF)_N&G>[S4?9.(6THA:$A)*2`FE<\TY5PJ6JVW
M:/<F7U/MKDC,I2M*E=:"@42<:(?#W`Y$D?(;9+EE.4I<9;`QRLT4JL?*-R39
MF@K]PN3Q*[G]2*B0=@$QTP`?OJ5<ZE--<3\KRDK4>HTZ]:8K?IFQ<WN>?<K6
M44&:3D:>']VM?IC7;;YQ>M5B=L#6%EK$XB(UR_2@H%H=],RJB!!.#&.9I@95
MR[6VV(0H"81]`$=0M`JI(.0*DCX5&?PQZM?6L,+(!KY:J>^APA7PTW*QLK]R
MIK4G3)]PTO>;KC?#66-9"ZA*8]>/U3GI%S<MC+)0EK;"<`.U7%-<@E$#$#5(
MYRE*D0\P"(XI7J-J=,1[TT6]][/"TG89&?8>)>O;%J>;^8FE^.])I<1".@/*
M9*JL^>W2"96]0BU(*1!5*#?RJYDFR<U.`82-$1.!U#!T`=9_3]#?ZDXHJ'],
MCZ:XU>L:W/TMIL)/E[TDGIKI4Y8)&P6KEC?\.\79_CU`(X\>*V&J-LI0&3X2
M3;2Q:BQC2MY`R38$2G1;/")?(BN<.PY3E'?ZZ!MQ[('Y(N+B3)`)3F/;EKK7
MZ8*JD7V18[;^DMJ;%4[M=/#[!E2N*U\A/'RAYGOF"K#3<ZXNPMSBQQ*?S#@M
M"QW.OQ$[>2)I?YW6F]5<OT[-9(1TF!]P:HJ]F_7;1CC%P5"0M,AA]^RJ"JE"
M5%*1W50$4IKC-SNS0KG)AR(\R/'YBPW_`"4K6A"W`:%6P*4%*HJ@.T'VXF%3
MYRYKAX8(')?"_DK*WR#$L;/SE"Q3;'5'FWR`"DO*5UXO&BHXCG*I.\.T3!VF
M]=@T+E<>LKZUO0;BRVV34I44U`U(S6-1D*C&QGE7)HS2(]PM+[L\"F]*5;2=
M*_TSEUUTQ8_'IOR2NF2K!EW.LA#U&KR\,1GA[#J+>3B;!`)?(H=W)6]C)%16
M6E54^TIBD(()AZ[:Z;B[;FH"8EM25,U&Y8%1\2/VY8(VG]>=G.2KEX7=IHC0
M_+6GPQ-^*A.5"2.3QY+O:N]3'(T\7&O\OLWS1TE2RNE"QQ)0'B20*_X8`)#D
MW`0Z@.LMZ7;6XS`MH*GBU1=!7Q[CV]FN-UA5<WGY:KZ-E%_R@<O#0:5ZUK3"
ML<_8,H=B\LF+KG6<STZN5XT0A/\`(2G)VN$16<VN`*BA2(6U,!?D%@[FT1*9
ML@Z*19;;N(4VX:=K;.D,<(<C2&7%O$*"5[5%.@H:T(`S[],2R\6VW2_4"--B
MOM--((\Q!6D%2@2?RU!)K[,<,LX.IDQY8H"[U/,E$@<<JUAO.\EZ0:V5\S=Y
M;H_9G5X6W,TI("P\@\8@FJW1?$344+L8@&#8=9[;=)[7%7H;\92G:>%S:2!K
MH=OM[X(2[+:'^>1[G:9;2(@-9#0<2"3E^[NKWRIE@H^>N6+Q7LE\<ZTPQ?<+
M%@Z-NT=-Y2FHZO2#BHRT2NDFU@H%"73;A%`JS?"FOVG4[#D```=!>-QX[K#S
MCS@;G$%(&O2NXYCO3X8+\UN=VC3HS$2*7;=YH5OITK3:/">U:5ZX:^S5!5HV
M<(I*HIJ-4%4VQR^Y(#I$.1(P!W!WIEV*`!OI1<;DH<+54J&\^*O2OX8HD=_S
M5)DJ2ZA!;%4;3V[=Q[L9_P#A1?+-2.?G+MACJB6RU\?\E9`3;RSJJ1JTZQQW
MDQ@J<D_(6=U#_F,(0DD?<3)JF(MZ"8`U3N0F(_QR*P]M;F(-0K0*UJ`32HS'
M7IB+<+=O%LY9)_3D?<VIUU6X@U*/]0&ZF8ZTUQ\9MDRV(^9A]=!QG;G$2>@+
M8Y;55"*6+>")D^!(,@+PIP_-&AJ(['![\0);"(]X[:^26$-\$:0IP*/GK-?@
MWE7_`!Q\:>N@]772I"O++8I[OYG]M,%WY.,DW.LRG&.*JN.K/9`C\WU"X.91
MA#/7D8\_2UG!"U*+<-D5"N;3)I&$R#<O<<X!T*.@'%VHZA,WJ`!CD'/VC/#;
MSR;<XXA/,L%THFI.VA\62O#H?P.&0OIBKVK&CR3R##DK].FJRNK;HF_H-X=O
M&0KMD)Y%O8RR8HMF#=N@<Q5A7,0I-AW$-M+K;4YJYH5;U[EI5X=M22?8!G7Y
MX<7G(3]DV7A/EQW4>+^!%>ZL@FAIK3IA+/CKXXXQP?SDS=-8$SYC_+V!KOB]
M.6Q]6Z7>:_=$,?H*60RCZ%CW$'*R2)(LCPR@$^/<@>F^X;:?^4W"=/L,95R9
M<9FAQ0(6A220"D`^(#(Z@XFW"N/0+5RV9+M$]J3;E-(VMH<2L`T57)*SG\,-
M&YM5;'%TXN9BK.59ZMUBJ2E,DT0G[;,QT##1DZFW55K;A62E5VK-%P$P5($@
M$X&.<0*7<1TH<=D2&+RT]$05O)7^4`FH(SR%<N^1TQ0.3QHLKC\E$YWRHRD4
M.=`,\JDD`9TPH_CW@2F1?BIR7CWD'FS'E@M%AKDFZD[]8;C`LTX%<`.?%S22
MEI602*R,W=$3!H"AR?,(@"?<(AINFW><YR1N79XBTI`HXC:17/Q$@)[>S$OL
MEEM\?TY?M-^F-KWK46GMZ2E.2=@WE1`-1I4:X,_Q28]E<><<H.+R/D&$R-G1
M9FR&[3K61:O9\M:2,8E,;RJ`*G?(-"Q0A\"JA0(J7J41#0SF4U4R<EUIE34.
M@HDI(&ZGCZ#/=7#;Z:Q&;?:VXTAQ+\]*5^,$*JC=5&8)J-NT:TP.'F\L-C<5
M#CG4X:N/2%C\\4:^#:9)`[:LNY&!<*&:4N-D50(B\N$V43@T8@(++#MV@(]-
M$?3IJ"E^4\M8\WRR`GKF*$_(]LJ87O5YR8N!";0DAC[E!)T&2DD#.@U%![33
M!2<JJ_A;E7PE-`\C)>-XV(W"-8HU6;S7(Q.-I*DY$;D2"N/6KNW/8=%*0-))
ME%-,A_E5(;V@(]-![6)MHOKR[,52H*B?-#0*Z))-:A%:'76F#G*FK;>^,HAW
M=2(EQ+8+2W2&P%;<J*7MU-,@<0;!N7.1=/XD9'H6><97J[9`Q-0Y:M0]_K-4
MFCU[+,&K#NV4)88%ZHT^&5(A%G35=+H&.F)0$V_UUW3X5H?O"'H3X1'4ZGP]
M0:"O7^*N,MEGW^/Q-^#<(ZG%M,*`<S*5BN1"J4(H=:G3%->%6POR\6+?C:\5
MM4T'$3UNFI.^_"E^V4Q$SCMR:2AD["8ZL6H^AFYC)ODP6$42[F.!0#6WU+C,
MQKTR]#=+SX2BB0<Z[CGU.6NF>!_I+(D2>-*C2&PS%*E[UY$!.T;@3D,TUSKE
MKB-\?82T<(+#D.U\29B-YB\'\AWF<F4:-@5TEENWXONKM<59V+A7%&<3$2,6
MD[,)5$1,"B)@]Y0'79(4S?(K<3D?_A3VT?RW'04!0RT*]M:Y=3CG9FAQQ^8>
M-E-QL+SA51E07L74[DG9O`S*NVFF"!SSEG)'+7"&1\2CC&\\5J%8*O(-<KY7
MY'UJ1H5=@*$X3`LNM%34VWC8AM*E;=PF4<JD02#U-ZZ&V^'&LMP8FQ7TS9A!
M/EH&X@T4*!*2JN6>FF>"MRN4[DMBE19T55M8W"JWZI30%!S*P@#.G7M@N<9Q
M]1P)PYJT3B)\^S?3Z)C%%A4I.BK-+>YNK!&/,BV?0CFOJOF4L18Q^\#-S*$$
M@"(#TT%NTAVX<A#LQLL*5(34*&V@)[$#3KAAM;`MW%4L1'!(4F,K:I!J@^'H
M02#TI0X6QX/;58F&-LHX^F*I*.45LF7"X-K[#M3NZ4567E5UCU-W+HBLU0M$
M4*ARN&XG[TS%$#%`0TW>H:&OOF34?TA^`PA>DCUR_3IP6@_\HT^>.'FXL-@/
M#<<JS!UQ^)(G+=>N2MB?H`C79+]/<!M48I^J9-)W:GP$_P`!L0PJGW#8HZ^>
MGB6_.EE1'_&5_M7CL]85NENW42:_=)K_`-R,.JQA:WETQ_5[*\K-AJ#R4A63
MAQ6[1'+14U%K?C$*9L^9N"$61/W`(AN&_;MJ?O);$MRE/ZBO]QQ48JW/TQK(
MU\E/^T81KSDR):4_)EPVFVF/+.NWQ6>TMXN*&.=)S&3"SR((/G%#9*(`[GTH
M(H][@6I%03*&YM@ZZH?%FV5<8G@J`J@_#\N)-S93O_\`?VS:#0('_P`\/Z;.
M@>L6[M9JNT_);HN%&CPOPN6X+)@H*#HAMA(JD!A*8H^@@(:F8*O*33N!\/[=
M<69#_P#,51O^92A[T[Z8STS-<SAQ#SWF'/O`&P53E+@/(=L(.:..^.79\F6:
MA7Y/N+(N81A0EIA2&D5`*H99%R0B@F'82[ZJK3EHN]K;A<D"HKC:*I<6-@4:
M@42I5*@@U(KT^.(68]YXU?7KCP92;E;'U$.LMJ#A;<.940@KH10C,#7$0Y.L
MV?D2C*3#<HPI7`4D-)E?T2R9SDTL.YW=V1)%0(]E1VUZ=UM[-0BST"F=$1*H
M'78`WUW0`QQ=JMI__29<T\K^8$^_;N"33W5QT\BBGG(VWUT65]L9^<?)*O<5
MELD=L'IP5RURBI[IGQ=Y$8TMEU/36"+2E<GZE4Y=3$5WJ;=$/T=W)6PS?]'6
MF5&@$`XH+F!0>NX^NEGDL*TJF+N$)]/W2VTJ4T<E)44@J24UJDA51F,.G!I_
M(6"W9KE'6NVLIVM2*$I6@9(4E5"%;DT((4<45-XO-A?F!E_E#P2R+CK*;J6!
MHUY><7Z988^ZW(DRU$@(2C&L5"0DY:`M3@NP_"\;I'-]MM$$RS<+0Q;>3-NQ
MVFR5-/%)2E2B*;2H@`T%32OPP!;ML2U\IF7CB3Z),QT`2&$+2IQ*00:E"2I2
M0305*1@JGG-O,MQA30^.^&W)*K7:;1,T@Y3)V+[-"TR$?K"":+NRO",2JHQR
M)S=Z@@(#V!H<W8K"PL.2Y[+D>F:6RG<?DLD?+#(_R:^SFC'@6R4Q(_C6E>VO
MQ0*_/$A98CB_]'&0\?<WLJTB79W)"TN,L7N1L$9`4ZJA/N3G29-)>Q.6["(:
MUW<I4CN%$Q*8`^^LDBX+_7TN<?CJ\MM(%`DU4`!4T`J:Y8V3(##W$U1N6/A,
M9P_G40`DU/51`&=>N!*XUY`Y'\+*C`8?E:;<^9.!C)`."\OX&KLWD%\VH2HF
M/"-;5+PS>3@W2#9J8A45DE@3,0-RB(:,2H]JY"LR7W$6^:D>-+E$E7_I44$$
M=Z'"S89EUXA&1"BL.W?CKG])QBKB4`:U4@."A%*9C!%Y;5?\H:DP/FE-SQQX
MS0DE'R.3(_,!1Q]-VETS<HJQ41(2%E_2XQC6UI$"%,8Z@&5/V@7?IH(AB+;'
M3]FM4I^AIY>?^TJRTK@W>5.<CB>7>DJM]B_>+IV=.Z]@TKB;9#C^2ZF=<?ML
M:R6+F_#5*DPZ.0V\W\RB[FM?*=&;/"3*/=$)M1K/<*9SJ@';[M^WKKE%_2S9
EW$2J_J@W%!IF5?NCOKC=/5R9-Y9-L#1XRHH#N0R;_?/;\N/_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex5-1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1logo.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0.E:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C8M8S`Q-"`W.2XQ-38W.3<L(#(P,30O,#@O,C`M
M,#DZ-3,Z,#(@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z,C1"-C0U-S-#,C$T,3%%-$(T1#%$0C5%-#!&
M0D0U-S8B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z,C1"-C0U-S)#,C$T
M,3%%-$(T1#%$0C5%-#!&0D0U-S8B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HY.#$R-#@Q8RUA.6,X+30R9F4M8C1E."UA
M,#@U,C%A.&9F9C<B('-T4F5F.F1O8W5M96YT240](G5U:60Z-&0T-F9A,F4M
M86)D-BTT-3ED+3DT,3`M86$W,3=D.&$W8SEE(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YG97)M86YR97EN;W-O/"]R9&8Z;&D^(#PO<F1F
M.E-E<3X@/"]D8SIC<F5A=&]R/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z
M4D1&/B`\+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_M`$A0:&]T
M;W-H;W`@,RXP`#A"24T$!```````#QP!6@`#&R5''`(```(``@`X0DE-!"4`
M`````!#\X1^)R+?)>"\T8C0'6'?K_^X`#D%D;V)E`&3``````?_;`(0``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("
M`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`)`#@
M`P$1``(1`0,1`?_$`($```$%`0$!`0````````````D`!P@*"P8%!`$!`0``
M```````````````````0```%`@,'`@0$!0(""P````$"`P0%!@<1"`D`$A,4
M%187(1@Q(B0*42,E&4$R0B8:,R>!4F%QH<%#-#5%=K<Z$0$`````````````
M````````_]H`#`,!``(1`Q$`/P`U_P!P=DCH]7)OFTSXVYO'F/LAF-M/:^/K
M%A.VOOM<:G*,J-*CUHJ)0I^H+>)3IZ2Y60B%3HBLS;-'(.!*L)SFW@.$!_L]
M<^E77PL[FCRI7RN!6%97LMA<=M>2'=7%GIF=JR1H"N8N)IB9;%=U`Y<20MJ4
MJJG$^(CCNH#+)^A=\,0N@[`M@S1-<O4(NKFVUP;:95LNF8>Z]I+0T+75K,GT
MS55J*WGJ893-:3]Q6K:[<\T&%D$(R9D:5EZI-%)**E4`%HS`?D,&(7\<H>1:
MR>2J(J".M/+7@J62JYO!HU755Y;S7#N[4D\K3Z+I)B[5<5I.2,;%.%!>JG6"
M.:LDU3&#$F!2`4)E;`M@6P+8%L"V!;`M@6P,CF%R]6TS06RDK1W:;5.ZHV5D
M(F5<DI"N*QMW.D?P;PC^-7:U/0LW`3[8J+H@&,F5P"2H?*H4Q?38,YG-/86[
M=K_N'[:Z8E#YRLXL1EANE="R.[&GS"W"?U;`4+<&F(VJ*JIF.J9[+K.5#H'1
M>MV3I8JBZ*"B>\90Y-\P:(V6+*M:3*)0#VV]G4ZW+3TG4#FJ)-Q7]RJ\NE/O
MIUXPCXUT\4J"X-05#*()K-HM'\A%1)L!P,<$P,<PB$CM@6P+8%L"V!;`M@6P
M+8%L`5_N(Y,T;HRYZRIJI)*R]MJ;IQ(RRI$$A5J*Y5$PZ:9U5!`A.(9YNAC\
M1'#8*J.H]2M6:%6LADQU*K8QW*6"S*4%1,=>FGXU5-C'23V,I6E:'S`4N"*G
MY!G<U3_3ZK8%*7`9@#F``W``0T,:0K"FJ]I*F*ZI"7:3U)UG3T+5=,3D>?CL
M9BGJACV\K#2C18@"51J^8.DU2&_Y3!L`YM7C.M,9(,EU:UG;=N6:S&W;EX/+
M[E7I!$4CR%3W^NVY&F:)%FU.LB9RE3)W*LLL&.X)&.X80`^.P49-3G)1&:?6
M>/0,L$E(,YBMH*/M-65ZZU<NTQDK@7QK3-BE4]TZO?OG3A5W)FD*ED%6[-0Y
MSGY)L@3'$NP:/5[ZUN?0-`2-3V@M$E?"KX]PD8*!/<&%MHJ^C")KJR#IG4M0
MQLG$\ZV*D4$FZI4BKF/@*J8`([`(3(%K%7?U)*%N=<C+MD!J=K2=JZOG+;S+
MNXV8^U],.Y.XT"Q9OWM+Q#*,@ZB,=-))^D!WRYD&Q3'#=$X8B`=1D6UL;5YO
M<X=^LA%QK-5?E5S56*4=I.+:W%K6B:M-71H0YNZR4=,4@Y582*\`T5;/>&43
M&=1SD'"?R)J@0#!5O-53#T;4<S0%)MK@5?&QKEQ3U&NJD;4>WJ.51`.!$K5,
M^82;6#*X'$.84;JE)_$H[`$&G-9ZZ$\3/0$]D5J2UK/3\85)&W[JBL[^6VF(
M5A<)*@7]94%2-'Q=*LG<U7@URZZ>U15;`U*3J*7KQ1!(0>VG,^V?H+"-;XW"
MTK:DHEG'VP/<NL(5[FUL<E+P\?&4TI4<X5*&5;J/T54FK94R+9R9)T'H14I%
M-X`!O\G.K'F*SY9?*9S.Y;M."K:DM-5[ZI8Z`?5#FDL?2TZ[=4G,O("834@W
MR2IVNY*,%4T^(J&^!=[T`0V!LFVM!F$?OB48PTZZW7O](9TY+*9#970O-0![
ME*P]$V5:W8N==^5K5$JEM(NDJ<Z_$@@J9X9HLR>$4,X*HLBF(3Q)F<S_``I%
M65TRW;8!+O'*OG)L.`HA_'B&38J)>G\1`Q@_Z=@C3IN:Q$EJ17RO?:FA,H==
M4+0^7.<F*-NI?B0NI058VR2K^.=N&3*C**?4NW4/6[^349K+BJV,FBV9$*LH
M(`JB50#9[!GP9XVYC_>596%@5;@4M4Y9#;IG")51_P!KGQ-TJ1C@H8V*?P`,
M<!#\=@T']@^.16>-X]^XCF9)&009NEF,>HZ*Q(_>)('.U9G>G36(S(Z7*4@J
MB0X)@;>$!PPV`#]$:RM\;@9U;NZ?M/Z<M9J9E;(T3'W&KJ&<YG+,-*."C9<M
M/*1,Q!5:Y9HA*A()54R,1$S5!<@*#Q"$$N`@\UR]2#-;9>O+(T3=?36K*E&>
M8"X[>SU!UXUS.67J2AV5SYJ%EY2CJ6K)]!MG4Q3`5@[B3,V;HS%9$5S@7$38
M$,#=Y1M9"L\U.>.\.0UUDDK*S-ULN?#>WV<U[?*VCU&F:=7<H-&U145%TXRD
M7MR8]XJ_9JI&:&;D%J\25,<N\!!`TU62D[%4S.R5)T^A5U3LXA^\IZEW$TC3
MB%12R#=11A$*S[EF_;PR3]R4J9G1T%2(`;?$H@&&P"5RA:G5^\Y:%[):V^02
MI6-+6-N3<:R\Q5$IF/M*I$5O=FV3H\945-6S=MF(L:EAF\P3ECS"R[)B0V.`
MG,4Y"@W>5C6@JG-_F'S!Y8K4Y!;WL[G94Y\*8O\`EK2[%AH&GZ'G5)26AFD<
MTEFM9RQZF7?R$(Y!$62*A!32$YC$#`!#V+5ZW5KIK4*1TT,Q-@KGY2LQDO3R
M<Q1HW.JRU]1T17S]ZU))0,%2-34+54TC(/*GBDW*L<8Y$@<+-5&V!7&ZF8#6
M/':J3-^JP;=2?-&SA1O'%72:F>.DT3G;L^97P0;BY5*!`4/\A-[$?0-@$#;_
M`%3KJ5SG6J#(:MI^WGIN]%#412-UKB2<E>"P+N@*5M+6,TC"1M=(5'&5JZ=U
M"F9V94A8]HS,_,J@=,R9!#'8&+^YAF.3TH[B4_Q!_P!P[[Y5Z$!,HX"[3D[_
M`%#R:[;=_J`6\2?$/Z@*.P/'K>Z=K/47TV+GV7B(M!W=^W]/-;M6!=;B1'+:
MYE`Q"Z[>`16%)0Y&]<01W<.H4,";SLAQP%,H@`G?M'-1=U?O*9561"ZDBY)>
M?)JL+6C6<N849N6L9,23A"+CA1<D1<@ZMG4YEXE8A\>79+,28`!<`":=N$#:
MGNL35]Z71NN9.](Q[+6BL\GO"O3=R,]E6Q[<;KUTUW'"C232LE3RB44U4`#`
MC)"15,0$QM@!)]U6Y",U>-(>8,82E:-;<.14-B40*PS.Q[H3F$0Q`0`^(_AL
M%_QP`<!R`_,`HN-X/AZ"01W?^WX[!5A^TS*`9-LX&[@`?N!WS'`0QP`(ND0P
M###`1+Z8[!'R\6E2_P`]M<ZFV87+/425F-1?*KJ:536>66]<6L6)?3;F`L!8
M&70M16,P!3&[8FG1U09*K`HBP>.#<0AVB[E(X%TT>-6MAG\HRK[+WWI4]D-0
M++@Z/269VP,RW-#R(3,.HG%.KAT9%NE#*KTE-/T_SD$SJC&N5`()CMU&ZZH=
M7D8I.F9_.7K*0L[`0TW#RN:JQ;J4BIB-:2D;(KMLM%L9!JH\8ODEVC@[:013
M73$Y#;BI`,'S``@!!,V*0)94\S)0'$/;Y>D<1#YA$UNJD,8QA_J,8PXB/X[`
M%'[4L`-HHY="B&(#6]^`$!_B`W=JL!#_`(AL!]D;96\CZI7KYG0](MJ[<FE3
M.*Q:4W#-JH<C.-8-A,&6G2M.I'ZBPIF-1<F%03+(1[8AQ,5$@`%?+6ZSOWAG
MZNMIH^9!)!1[G;SGL!85W5T4X5X66K+E()N"UA7U0N8X4G$!*SD$FZ!NH<4E
M&\<DJL00669@<"_Y!<DEG=/3*_;'*U92/!O3E"1`'J&><-TDYJX%>21$G%77
M!J-<A147F:EE`.INF.8K9L"3=/!)),`"9^P9[.>;_P#9=E3_`/E66;_ZP>[!
MH2A\1_Z_^X-@_=@ILP69"U^6?[J//Y5UU%*T2A9C);:.`8&HFW%?W/DADC4U
M9*3`KB#MW3=33+1H=!F<.840*@4^Z4QP$P;`<*QFH98[/#G#K++/0=#/:HHN
MR%F:'O\`3-3W5M77=OJAA;JO+EJPM$ITW2]T:8I]\HC"QD<K()R[=`#H.Q*1
M-0!WM@$7K$,5=-[5BT]M8*GD%8VUMSYA+)?G.<-$U!9J4K5*"C:C:NG3!],`
ML(8ZBHJ'$1$].-2E^;=Q`Z^HWF+J>P64RJYRSHMYF^]XGU+6!RO,&RG,!.7Q
MOG((T=;]\U%L<_&C*8ZBI4#LY<2ECXQ4_J`>H/%DXRPT9DURTV8RU4,H+N)M
M71C*&?SBZ8=2J^K'0GE*VKB96P*9>9K.K7SR2='.`G,JY$,<`V"OGHCD*760
M^XD``]0S*6U'^&'YTM=LYO3#X[P?'8/ASWZ7]NM3W4%U!:&?2Y[;Y@+6Y9\E
M%=98K]1?-(5!::Y;.2O,]9+<RP51>J4O.O(UNG)))&*N0J9'")BK()[!)?1T
MU5KDW6JVK]-K41B"VKU,,MC<82H&DNHBVC<R-&0;<A6=UJ%>D(DQFI5U$\-Y
M()M`$CQ!0'[<NX=9)L$GK?Q[0FNSF1D2(%*Z>Z8^64551*7B8$S&7Z3`HF`-
M[U*W3Q]1_D#8!P_=>7LI&A,G>5RV<I4,3'S%P\\]AYH\:YD&R3\]*6Z=2\_/
MRIFQU053BH]TNTXJYB\,AQ*`CB.P6BHV08247$R<>Z:OXY^Q:.F+YFNFY;N6
MKENDNW<M5T3J(N$54A`Y3$$P&+ZAB&P9KNK;E\S3Z0NN;3E]]/-D,-)Y_$JH
M"SD.TBSNX`]PKSJ!0=U[>J1C(6Z(I,JWGVE1QY3&*1BHZ;*D``;>@7V-.K)U
M3&0O)[9G+)"..LRE&4YU.Y-8N#JKR-P;OU:Y5J"Z%<R;M;></G-0U?(.E"**
MF,H5N"28C@0-@I)?>$5M`T_J1:<<L28C3.J#MRPJ2>13>H'7A636^",HU<R:
M9%!.Q261CU3D%0"[Q""8/0,=@T*8N=BYVFFE2QL@P?0LQ`-YEC*LW2+A@[8/
M(\CY)Z@Z0,=NLT5;J@<JA3"42CB`X;!5W^TL=M'63;."#=R@XW=0"]QC<%4B
MFZ1Q$4>J@8VZ(X%72,!B#\#%$!#8"):6571,]?\`UCXN+=-W;FGM2NIRR"":
MJ)A2.K86RL=\X@8P)@+J#7*`F_K3,'Q`=@C/K':6-T+AUI2NIUIOR!K8ZE.6
MYJE.-485))M$YFZ#AD<).V-<,2\%C.5`XA2*-60.1W))L86"P@`MEFP>!]O%
MG`EL]K[4<S/5';9]:"K:]S*VNB*WML_77<JTK7-$6#HVC:P8HF>(-))LR-/P
MBYD6[LHNFJ8@DJ)CD$1`Y6;U=%ME/S/.'"J:#=#+Q>I1994P$323);>I#&.<
MYL`*4I0$1$=@"9]J*X06T4\O!45DU3(5[?E!8$SE.**Y;MU0<R*H%$>&J!%"
MFW1P'=,`_`=@(GJJ:D5J-,/*=5F8&O5&LY6KTRM)V.M<1R9.:NK=>0:J=`IM
M@U0*H^4B62N#J5<)D$&S),PB/$.F4P0;T-=.^YUDZ2N3G]SI*FJO4)SW."7%
MNI+RZ13/K2V^FSH2U*6;@R8&&$29L`;*239$Q2H'1;,@Q*R*.P%HO=FSM18:
MXV7ZT542"\I=/,S<IK;6V-!4^HR>U0\,C$2E0516C^+6?(.&=#T/!1"CF4??
M,"8&(0@&.8`V"3R)O0Q1,(B0VZ(F$!'X`)O7XX`;$/7\/3TV#-IU)LQ]H;9_
M=PV8O#5=;4]'VYM1<K*]!7!JP9-LO"TL=.@XV+FEYAZBJ9!B2GS3I#/-\P<N
M!#"?#`=@T;(.OJ'J&+;3<'6E)3<._13=,9>&J.'DXIZV5(!DW#-^R>KMG#<X
M?RG*;`?CL`C-534\9Y5X>SN7S+95M%5EGES8WFMK9JQ-!)+1E8*TNTJJL(..
MJ^Y]8TRR>G.E3=,TVX<\N5SPBNGZB0%Q(142@-K+%.1#/[L_/U$O)V-4E97(
MI:V.:$%TV0<2LI$P-AW,LDU9%.)A<MTD%%5$2[YDDP$?Y0Q`+"V8"5RYY:"W
M&SY7D6C*1=6NL;+4C5MPWCY=!4]KH>95KQ.D6\<H\1CY.2?547%@F"9W2KI<
M$2#@H("$=\_^5VG=4+35NK95_3S^GY&_%E(JO;;1]6LD&]0T/<U*(CZYMD::
M;IN5VT=,Q51I-VC\J:IP(0ZR8"(?$`@:"U[+U:DK?+A.9A*1GH>/TB+>5+8R
M8/4HMEB7*S@RW4+<Q]9&2P4$9"TV7^*!BL*@\5.;GG"J>!1)L%O@,`#>$/40
M#$0*.(^GX8;W_#8*I^B$[:N-9'[B0J+E!8XYD[;&*5-9,YS$0FKO-U3%*4PF
M$B*Q=PP@&!3>@^NP$CL%4T>OK9:BE*IG25D664;)))K-P.3C<'J=Y"@(IB("
M`?7)CC\/F#\=@XC6.TFB9\Z3HZ_F72J1L=J)99CDJ_+1?6#<C"/Y%_#+#*M[
M9UQ*-$Q.I3DT[`Q6:ZP*ECG2QA$IVJ[I!4!XZ'>>>\.>G4AS15#F4M%*62S.
MY>LD-BLM.8BE'R0,F,G<^AK[7<E)2JX>(.7F8-E.LJ@;J&:"=5!-83F;J'0.
MF80^C,%_BL>6:W]U?B?R_P!S5#W1YR]S?7>M=9<]<Z3W-]'T[JF__P"G?1_#
M<],-@*MIA_MC<C<;]MGJ/;_3:2[RY7S_`-F<API/M3M7S)^A<GAQM[HGIP]S
MC?+N;!(#-/[+//>1;W/]L><?-E3^R[KG4N=\N^/IGK_2N3_3>+VECPN?^GZC
MRO"^JX&P2TN9VIXZKGOSG.QNSJE[RZ9U?G>U^C.^N\GV]_<'-].XVYT_ZS?P
MX7YF&P5)JI_Q!^MK>3/`_>6XCU'R[[G.^.'RWY'6.^OU_P#TL.'Q_7\/X[!.
MZQG[%_MMO+[<^_?;1QZ!\H^./>KVIR7ZWVIT?D/K^T>4YKGNB?IO*;O.?E\/
M8/!R8_X_/-W#_;_XG"[3JOR7[;?=WV]T?H)^N]P=L_H?>'1-[D?_`'O>W.4^
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M=([;ZZ/.]J=I?VOU7K6YS?#_`%#_`$>)\O"V!LD_V+^$AR_F;E^`CR_*_N-\
MMP.&7A<+A?E\/<PPP],-@Z7)K^P[[VZ=]JG9_OE[-K+M;N?W`^2.TNGF[OZ=
MYG^EW^F\3>P^HX/$W/3B;`3#/U[5/;?4?O0Z_P"!.X*6[E[;\J<[U/JJ?0N:
M\-?WOTWG<.9W/I.%CS'Y>.P5H5?\-KFW/5?:EU/FUNJ]R^>>N<_QC\UU'JGU
MW-<7?XO$^?>^/KN[!T$;_B`=/-T/V]=.P/N]O^YGE-WYM[A]*_(WM[>Q_JQQ
MQV!P<MW^*KY^I7VT>(/<7R57=B=H>XWR'Q>T)[KO9_-?J/=7;//<ER?ZIQ__
M`"GU'#V#T5/\6_S2[ZAV3[G.?6ZKUGW>>XOKG)AS/6^=_P!S>O\`3L-[C?F\
M#=P^7=V!P+B_XYO]F^:>M=,[RICM?S5[Y>S.\.K-.UN9\D_VIQNJ\+A\U\OQ
MW_DWM@LW_)RZ7+</A;C?EN6PX.YQ"\+A;OR<#<_DP^7=P_AL$,LD7L^Z!?\`
M]FW;?0O=9>_SOVWU##W-=P-O+G-]1]>)U'@;G`^BY?=X'RX[`_68?L[PG<7R
M#Y%[*[>5[F\2=^^2.E<RVYCM#Q?_`+@]4^&'2?J^'O;OICL%</)A_C\>Z"5]
MCWG?W2]Q+>3O'GON[MZKUIQSGGSK/Z=RG7N/QNZ/EYGB8?FX[!V]K/V0/>7.
M^,O=M[X^;@?('!_<.\N]+ZQ'=!\H]4^7Q_S?+\OUC]&Y?#A?EX[!9?'=P4W\
M.'NGPQPPW,#;V]N_T_CO>GX;!`V@O95^XA>[QST+WP>WJW7N![;Y_?\`$_=\
8AXT[]Y;]$[RY_C\IQOU+IF&_^1PM@__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex99-1logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1logo1.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0.E:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C8M8S`Q-"`W.2XQ-38W.3<L(#(P,30O,#@O,C`M
M,#DZ-3,Z,#(@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z-#(R0S8P-S)#,C$T,3%%-$%#,#(Y,T(U04,P
M,3`T0C@B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z-#(R0S8P-S%#,C$T
M,3%%-$%#,#(Y,T(U04,P,3`T0C@B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HY.#$R-#@Q8RUA.6,X+30R9F4M8C1E."UA
M,#@U,C%A.&9F9C<B('-T4F5F.F1O8W5M96YT240](G5U:60Z-&0T-F9A,F4M
M86)D-BTT-3ED+3DT,3`M86$W,3=D.&$W8SEE(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YG97)M86YR97EN;W-O/"]R9&8Z;&D^(#PO<F1F
M.E-E<3X@/"]D8SIC<F5A=&]R/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z
M4D1&/B`\+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_M`$A0:&]T
M;W-H;W`@,RXP`#A"24T$!```````#QP!6@`#&R5''`(```(``@`X0DE-!"4`
M`````!#\X1^)R+?)>"\T8C0'6'?K_^X`#D%D;V)E`&3``````?_;`(0``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("
M`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`1@"[
M`P$1``(1`0,1`?_$`*(``0`!!0$!`0`````````````(`P8'"0H$`@4!`0`!
M!`,!```````````````%`@8'"`,$"0$0```&`@$$`@$"!`(+`0````$"`P0%
M!@<(`!$2$PDA%!4B"C$R)!<C=4%10R4UM18V&+@Y.A$``@$$`0,#`P(%`@4%
M`````0(#`!$$!08A$@<Q01,B%`A1,F%"(S,6<5*!<D,D-)%BDQ4E_]H`#`,!
M``(1`Q$`/P#OXXI6.\J99QUA*DRV1,IVV)IE/A2%%[+RRXD(==41*V8,6R15
M'DG)O#AVHMFZ:BZIO@I1Z#R;X[QO><LVT6DX]C296SE/TH@]AZLQ-E5%]69B
M%'N:MOEG+^-<&T<W).69D.%IH!]4DAMU/[411=G=CT5$#,Q]`:YT=D?=UDBW
MRCFG:HTLM2C'*RC"/O%LBB6.^3ASG%)%>OTU,',3#&6`P"F1R$BN(]!$B9NI
M>;O\%_$[1:S'7:>1LK[G(4!F@A?XL>/W(DG-G>WN5^)?XL.M>;/DS\Z>3;G+
M;2>(\$8>*S%$RLA!-E2D]`8<8=T<=_8/\SGIT4]*B2YPE[6]I`)+62`V"LT=
M+E,=)2\SI:%7E$!'[B8(0<W)5M@@R$5NY'L9@E\]"#T#H&24Y7^.GC[_`+;!
MFTL$\7K]O']Q(#^TWDC65BW3ZKOW?K6'I>#?EOY7MF;/'Y%E8TWI]U+]I"1^
MX6BE>%`O6ZVC[?9?2K7?>L+V#4,Z$['X7FOO-CD.W=4F^4R1F&RAO\0#I?B+
M.5ZD8@E#J)1Z@;I_IY(1>?\`PMN`V'-M8OB8=1/CSJA_U[XNT_\`&HJ?\6/R
M+X^R[#&TD_SJ00V+EXSR*?6X^.?N%OX>AJE7MR?8=J#/M(&S6[*E>^HIVA1L
MY5^2F8A\EWF551;EMS4)("+"MU%5B\3/T$!`W3IRO-\7^$_)F&V9@8VNG[A_
MY&!(J.I]`3\)[>EO21"/7IZU1K?-7Y'>&M@FOVN9ML;L/_B[2)Y(V'J0/N%[
M[&]^Z*13U%C:U;M]/?<9BG-K^*H.=8UAA?(TBL@QC)O[RB^,K*^6-XTD$9=\
M)752?.%#`!$9`QVYC#T*Z$P@0=3_`"=^,/(N)PR;GB$C[71H"SQ]MLJ)1U)*
M+TF4#U:,!A[QVN:WH\,?FCQ+G61%Q[GT4>CY+(P5)>\G"G8]`!(WU8[$V`68
ME">@E)(%;G"F*<I3D,4Y#E`Q#E$#%,4P=2F*8.H&*8!Z@(?QYJT00;'H16[0
M(8!E-U-?7/E?:<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*Q]E7*-+
MPMCRV91R'+$A*?2XAQ,3+X2"JL*2/0B#-DV*('>24BZ4(W;(%_4LNH4@?QY-
M<=X_M>5;O&X]I(S+L\J4(B^@N?5F/\JJ+LS'H%!/M5N\MY7H^$<;S.5\CF$&
MEP83)(_J;#T55]6=V(1%'5G8`>M<LQ(G9SW(9\DIM1VM0,!T21,BD[?BLK4,
M:P"AA.FW:,@52;VO*,S'?XK@W<4J?7H=1!J5,H^A1R>`?B_PU,55&;S+,2Y"
MV$V5(/<M8F'$1NBBQO[*\A)'E`,3RE^:?D*7.9SKO'NODL&>YQ\*(];*MP,C
M.D3ZG-P!?ZFCB"BLL2>QV`-0Y]/`'K@PLSSGGI508&<SQ.0[B^R[^?1*+=XC
M34(Y$7<Z+=<QO(+(6,(@8OP5R4!/RW,?@W,_)>&>9^<]JVHX<!\D>OC<8Z+&
M>JF<L;1W%K?)\D[7]8STJ[<KR7X\\.;`>//QHT:;[R"3\4NUEC.7(\PZ,,8(
M.Z7M-[F/XL92/247-6)D#`WL%R2BG9MO=O:9KY%S**CQM7<JYM1J:H-W:13%
M;LL;4$Z<8W15!$2"B804*=,>XHF$1&8TW,/"^B8X'C/C.5NLB(A3+B8!F%P?
M5LK(NQ(O?N'0@]"!TJ!Y#X__`"*Y.@VGF3F6#QW$G!98<_9C'-F'HN%B$(`;
M6[39@0;@FY,?(?4@H.P<8N]B^M+^W(&3!BU#*U[QN[<'75!(J;&Q2[-NW!R<
MX]`(!P$PC\B`?/+TR?))^+LY!P??)K"#W'[/'R0+"]VB1B;6][5CG"\/*)OD
MXGY*XQ)N5MV+]_E8;&YM99I%47)]K]?X5D.T9GW^U8B&-8VAIS;/V!YT$6Z,
M=F)M%9?QC8V:C;PHA5,MQ9Y5W$216IOZ<?O"=(X`;P"/7K"Z_BWAGR'DOL/'
M^4VFYA#<EL(OA943`W/S8;]BNM_W?T[$7'?5Q[7FWY#>)\./5^5<)>0^/\BP
M";%8]C@S*18?;["/Y&C?M_9_5NIL?C-6^GIKCK<J'?Y!T&5-&6:.5;FR5JQD
MJR,FD_12R1C%0FJ'=I4Z,?::.JY`R1/M*$70$H`8X',5$.X?*.\\79*:7S(/
MDP'!^UVV+$QCR.WUCR($NT4X'4]@*M>X%@7J/7PIQOS7A2<C_'P_%LXR/O=%
MFS*LV+W^DN)DR62?%+74?(P=;`$]Q"5/+'?N-TI]=UXU^]7^WF=YEUM8PC:W
M6KM.Q-?F+3C+%<Q?WA)C&U%ON13G2,U<IUNQ1K8JZ#9VU9(=AW:K9'M/S0#R
MGR'1<JY]LM_QJ$P:;)F#(I4(6(15>0H.BF5PTEO7ZNO6]>J/A+BG)^$>+=/Q
M;F.0,KD.)CE9&#F0*#([1Q!SU<0QLD0;T^CZ?I`KHKYC^LJ4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE.*5SW>U*Z7C9O9#"GKXQ,Z.4[R0BK;D-=/R
M*,V\G(H+NXQ>932ZB>+HU10<S"I!^#J.4@_G*3FZGX\:K4\!X+M?-/)%':J/
M#C`V#%5(#A+_`,^1,5A!]@K>Q->='Y9;S?>4O)FC_'3B#D,\B9&81<J'<%D,
MH'\F+CA\AA[ET_F`K]+;)>5QS%X=]3ND#,T7:;K$-W&5K*S,=)_&U21*9>7D
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MV4M[,\C,R8HN4C$%4'3Y$Q.OP4Q>P+V'*?)\^JBS(6T'`N$D#[=<P(<ED/12
M(6[42X(-NR-KVZD&YQT>#^&,;=S:_)7E/E#R,&/W3X!D7$20`E@<A>^62S`C
MN#RJ1?T(L//D#'.NL3&G?9C]6>UNOU4(B@V<7_'M\L]D&)`PF,H_>,+5!)5Q
M99)ND<Y_.IT$"]!*7J!@JTN\YODSB+B_D+CFZV))(Q\G'BB[_P!%5H9#*`20
M!VC_`(GTKBY%QGQMAXQGYIXHY;QW4A0IR\/+GF^/]79,B(0D@`D][?PL+WKY
MQAC_`#-CF"4NNA.0R[IZUV=ZU@,EZYV>&%S.1R,D5,RD'DS#\@NHE'HN2]4T
M;##@EV&**@AXBB(U<@W7%MYF#5>8L+_%>=XZ&3%V<3VC8KZ28N:H!8CU;&FO
M<'M'U$6^<4X[S7C6"=Y^/VR_SCQAER+%G:>>/NE0/:\6;KG)"@BX7+Q^VQ'<
M1V`DWQOK<Y+U0ZY9&V,]3N`8'8S9V0R51,69WHA;'-[`HZK4VPM)JR2K*9QS
MC6:975JV5M\$RB2E>.4SHJ+IK*'%)($QTU\A>7N9>0,+'T6_R8LC6X4K,CI$
M(FF8`HLTH!ZN4)L`%`[CTN;UZ$^)_`GCWQ5L<KDO%L*?$W&R@59(Y)S,N.A*
MR-CPDCI&)`+EB['L7ZK"U?MQ'HAU=]E>4M9_:UN1B[+^!=HL@T;$&4-A]7X:
MTH1V/);)]4@*\A$-K/'S5?<WFO)HM(%HE(1R$@U750(1%?QN2N%5L45G.NG[
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5\*JI()G6643123*)U%53E33
M3(4.ICG.<0*0I0_B(CT#BE>+\O$]O?\`DX[L^M]SO^ZV[?J>7P?:[O+T^MY_
MT=_\O?\`'7KQ2M&GK0BFV:-N]W]PIP471$[H\Q_2'ZAE5FK2*<.E7#]RQ=.$
M_P!*:%8@(E`O0X"FBJ<@AVB7FWWGG(DXKXTXEXRQ+J3BKDSKT!+@`*&`]S+)
M,QZ=6`/K>M!/Q?Q(N;^8^=^9\_M=1G-B8KFY58RQ+LK,/000XZCKT5B"+$5B
M[!=\E:A@_>KV5O&9I++.9;]8,:X0!5$SEY%QZMC8T>FLHTH"Y$I5+$_9)&3^
M"G)#)E`>TW4;@Y=I\;9\MXAX'B?X^-ZO#CRL^QLKM\33SLWIZ1JY!]C.3ZBK
M6X%OLO3\%Y[^3LR&7E^[V$N%K.G<T:&9,;'5!]7_`%7C4KZ$8RCH#60`P6.+
M\?4O2&)M[NC-I7'<CLW[$L[LEC(V92J*&<"ZJC>P"*BR;NWRS1ZR3$1,9*)C
MU5.P_F7*I"_Y=_D&ZRO+&3C+EO'G+JN-Z]A>(3=+3&/H"(4:-SZ`S2*MQVH5
MN->!_P"*\>PO!F)F-@12ZU]WR_:*2)CCDMW0"7J>Z>198Q<DB")FLW?('D'A
M/6G(&7Z'$?1L%MTTU?.V$V+\%8.%G2LJVJK.$`+&7C-61UFTG-M[!:&?8Y/%
M-P!1)%4"NUSN._I9?*^>:;C.XE^6'&Y3Y`#?]WL,_NGQ(90?J@P<8%8S'$UT
M$S="P)C0):LA\'\8<BYGQ^$P9.9PKQ85O@ZO5]N-GY$!'T96SS2KRB:=;.8$
M^I58"9VD[JON9]>DS347$]K7M3L3C&\(@5RU9WG($AEK&D\Y11,`,K=3[<F\
M,^82"H]%SE6,*8&$Q$Q$`+R(Q?->+M&7#YWQW2;#4'H6Q\9</*C!/[H9H2O:
MRC]HL+VL6]35P9OXYYNE1MAXRY9R35[U1=5RLM\_"E('[<C'G#=ZN?W'N-KW
M"&P%1:>PE\Q;8[Y$Z38VU8>^V!C4,&3^R>/YY]F"GZ^(89R!D*10G+G67+2)
MBJR%BL+6I+."MVAQ<HK(JF,D<P)IN;7Y[Y&V?(\<<5PL[-RN#8>29,,9BQG*
M52G:%EE7N9NP,RJ"Y';8_H!>?B[Q)I^(Y1YOL=;KL'R5GX8AV#:]I5PG8.'9
MH87[40R%4=R(P>ZX!M<M*[2_U4ZHZ'9UVLV)P,QO[;(>XMP-=,JIVRZ*66OQ
M;]:QV2W.8RDQQHU@M%Q"]CMCUR/W%G[H.\J95BI%!,,75FNMDO%*C'M3N?JQ
MI#C]+*&UV<:'A"ENW9XZ*D+C)G)(V&22(15:,JM:C4)"SVN201."BC>-9NE4
MDQ[SE*3YXI4$,#>^+UN[&92HN',>Y,R:SN^5I$\/B1&]:\YRH$%E*7*DLJ2,
MI%IM=#C*Y).G!6R@)^5R@0YB"`&ZB7N4J9VGN]6M.]M5O]LUOO#RT(XIR/.X
MER97[!6+'1[G0\@USQ#*5ZT4^W1D1/Q:Y/)T34.AX5C)J%(<QTE2D4JMD_>'
M7/$FSF"].;7;Y)QL9L3%S]AQOC>LU:Q6B1&JU@C@\S;[8]A(YW&4FJH%8NNQ
M]*+-D%S,URI"<Z8EXI6(-Q_;'Z_]#)QA3-E=B:U5\ERS9L[B<15:+LF2\M/V
MKT"F9.0QWCN'LUFCVKU(1.W6>-VR+@A1\1CB'3BE>#5'VSZ1[FNLIP^%;]=/
M^K\*TU?(63:%D3#V5<6W2L4M`.AK`M"WVHP0OF9U0%,@-5%E3'#X+T$!%2I*
M:D[9X-WAP)3-E]<+2[N>'[^M9&]7L3Z`FZPZ>JU.S2]0G2*PEB8QTNS%I/0;
ME$/*B3O`G<7J40$5*DCQ2M>NK_M.T=W(V"SCJ]KSF9O>LSZ\K32>2:R%:M$,
MV;HURU&I4^^KLY,Q#&&MD=#V84VJZ\>NNF45TC@(D4*85*G](R,?#Q[Z6EG[
M.+BHMFYD9.3D72#*/CH]DB=R\?/GKDZ39HS:-TC**JJ&*1,A1,80`!'BE:4;
MM^XD]3M2M,Y4X38.R9?7JAG87"P8%PEF?,](JB;`YB.W<O>*%1IBJGCD.@&%
MRU=N6_88#`<0ZB"E9WS/[D_7K@G63!^X=WS8]7U[V.L;FIX=O%8QSD>R+6^?
M9!/E=QR58CJL>UQJ[=Q6'R)BNV2`^=`2``B)>JE8^UQ]ZWKKVKS90M?,-WS+
M4KDW)3^2C:I'6'7+.=+AW+N(@96R/2/[-:Z'$P$00D5"N#%,Y<)%.H4J91$Y
MBE%2ICX9WHULS[L;L?JEC"Z/YS-VI[FMM<WUAQ5K'$M*RM;4%7$&#*>DXUM"
MSY72:!^X62ZX)B40-T'BE77M9B:YYHQ#*4FB64]7GG#H[A%\FL=NIU4AIF*9
M/6RO=X`E:K,2C6>CRK@*"LE$MR*&2*;S)J5`K_P8V1^MT_OY>>[R_:^O]FL_
M\>_+=W]WO-W]/[O>+^J_#_\`:W^R^SQ2K"]0U?D&VC&>(M!NX1LKG)>7(Q9F
M/P[0F6]&KT8@U["`*B:Z:Z90Z#U'OZB'\>;:_DOFP2>7-/D.RG`7`PW#>Q0Y
M$CD_H00?_2M$/PXUV1%X$Y!BQJR[1]IL$*_S"1<6%`OZ@@@?\:M3%U:"0];?
MKIB2M@?0ZVU>$U+HCXO&BLT<9JN3=XC)E``\I$;(LU1,8_\`,H0@_P"H.2/(
M,\P^=.;Y);LRAQW.$!O<@C!@*E?TO$';IZ`FHKBVL7)_&?QOB1KWX#<NUIR1
M:P*-L\D,KCW`F,:F_J0*E/D&I-;+D7<./>MB/&]US5I30[D`]J:I<9J$Q\=Z
MQ47%4H?C7AIU\51,>I3E<*E,4P&'F/=+LI,#1\8FB8J^)JMYD0>X^Z'W/:P%
MOW+\<9!]054@BU96Y%IXMGR7FF/.H>/.WG&<3)]C]B1B=Z$W_8WRRAAZ$.P(
M-ZVCE*4I0*4`*4H`4I2@`%*4`Z```'P``'->R23<^M;6@`"P]*LR[UZ>M#*-
MB(J>9PL,ZD5V]X;KQ<@\D+#37T%,QLA!5^8B[!7WM/G%9!ZU<)2I!='0(V.F
M1'O5*LBK[5+&>.JSB3'U)QE3B2Q:OC^J0-+KHV&P3ENL'X*MQR,7%DF;59Y"
M6LEAD"M4`\KM\Z<.EU!,=0YCF$14J^>*4XI7*+I/BFO^Q#WN^SS9G:"'ALEQ
M/KJME!U:U+QK:R%L%4QDY62L3JRY%CZS((*0YK/)/ZTX>-WAR'5;N954P?XC
M9HJBI758YBXQZ#0KR.8NRQ[E!ZP*Y:-UP9/&Q@,V=M`53.#9RW,'4BA.TQ!_
M@(<4KEAWY,;TB>QUC[9JI#V%QHSN@BTP][%J+3(P\FM3<M,V;UUB/8>'@&X)
M)+/IR33,R?&$Q.]TX>@)S.)9/M4K)OK6QUE%KC3<_P!].UE,.&T>T.([SDC"
M6,)WN25P'IMC>J2-KPSB-BHL0QHN3OT9`LI696(0AERF:J*$(Y.[*92J7[9W
M6NIS&F27LBRRRA\G;F[W7[*66,J9QL"+>=N+>')D&QU>$HT#*/$U7%6KS1&`
M,Y68,Q23%9<$S=R+=J1%2M_^>XZ/_LUFF5^BS_)_V<R0Q_(_61^_](]3E%CM
M/N=GV/JG61(<4^[L$Q`'IU`.*5I/_:Q__#_43_-]@O\`V+RIQ2IR>X#<U70[
MUZ;#YZ@CG4R<-8)C7!T4V37<R4WFW*3@E+QTVBV34IG+]U%S$K^4413#O,UC
MU1#ITZ\4KFWONG"GHH@_2'O5'LQ8*8K?%U8]DT\V1*=6?AMO'SJXV>\6]\H/
MVY)GC;*,Y)E;N'"ACB9O%HAT`A"@I6PG]RED&V72C>N_0:L72;I%(]CV[6-L
M(YBM55<*)/W^&TIFL(3]:;OFKI(3-)^2N,>X43Z'2=HL124$43G(HI70KA#`
MV'=;L857#6#,<U/&.,Z7$-(2`J52AF41&-VC1NFV\[HC5%,\E)O03\CIXX%5
MT[6,9590ZAC&%2N8O]T[8(#$./O5-="5F2=U_'_LYQ3>'M5H=?3D)Z7;PL?/
MV:6CJO6V0-RR]CFU4E?`V+VG=O%@`1[CB/%*VEZD>Y3".W^=:U@:F:J;\XOL
M-G8621:73.NJM@QAC6/)6H1[.ND)JXOIAXWC'<@V9'1:%.F(+N3$2Z@8X=5*
MUI^H[_\`0#^X'_SS7O\`Y7+\4KJPXI3BE:P=&&:>)]A-ZM<G1`:_C\P1^=J@
M@KT,K(T[,$,BLJ[26-XS.DHV3B2ME.T@%14'MZ_(<S_Y=E;D?"N(<XC/=WZQ
MM?,1Z+-A.0`1UL61RPZW(Z^QK5GP-CKQ#R+SWQM(.SX]RFUQP?5\?81@E@>G
M<$=%1NEE8V]Q5J8OQ7(R^#=I-*6CE-A?\#95D[EAH7ARH(IUVQ6@F<L"SC8>
MXITHE.RI+Q;DY3F%([-<HG[O@)'D'(H,;EW'O*LBE]-N-<D&=V]3\L47V&PC
M/ZN8BLJ@@7#H;6J&XKQ/(S.!\K\'0L(^0\?VSY.M[C8"&:<;352K[B/YP\#D
M$]ICD'=?H,U+3];OT=&9J<-'L=C3.=&CL9YM:`4Q)3$62*A*R"-:L4ZD8IAC
M'-+M+R0@Y5R<A?I.46#A40:H**)VJN'GZ:>3BJ,C[[49;96"?Y,S%F13+'&?
MYQ/$L<\*@GO5ID7^HZJ;X?8ZSD.-%SB1'BXQOL!,+9KZ2:_-QY'$,TH_D;&G
M:;%G<@?$ZX\C'XHV996UJ]F9$:5O(:[:$MC=$C<)1<"LJU<@12$0FZO)*F^D
M<7Z!/.K'F4^VR,)BB4Z12+*8ZS].)2V=I`TNN8W[!]4L%S_;E4?5])^D26['
MZ$$,2HRYJ]^8%36<C98-NHM\A^F')L/[L#GZ3W@=S0EODB-P05`=KHE[Q4()
MN+F3L42@4>PJ2*;M-V^=J*@)D4&$:S%Q(2+I<I1\:2"2BBG3])1Y'XVIV>8_
MQX\$A/N2"%`'J69K*H'N6(`]S4KF;W38$?RY63"HZ6`8,S$^@1%N[L?954L?
M8&OW8YZ$BP9OP:O60/&Z3@&DBW%H_;@J0#@D\:F$QVS@@#^HAOU%'X'H("'.
MG/%\$S0]R/VL1=3=3;W4^X_0^]=_&G^YQTR`CH'4'M<=KB_6S+[']0>H]#7M
MYQ5STXI7+IGK7'=#U9>S3.'LFTMUXL6YFK&[<174=QM9\9O&+7-]"R16""2/
MRSB^'D5BEN:#]RNZ=JM$`45%>3?I+D02%L\04J<^O7NBK>RN8L<88I7KX]FM
M/E;G.A$6VYY@U8?8UQMB)J5)ZHO,W^X2EF=-$V*1VI$P%B1WW'7)U$H=1!2L
M<_N8J!?<G^F_9^E8SI%PR)<9:8PF:,J5#K,W;[-)$99JH;YX=C`5YE(RKQ-D
MT;G76%-(P)))F.;H4HB"E;9L14F-M&J6,,<7N#.XB+%KW2J3<JU+MEFJJ\;+
MXWC8*PP<FS7*DX;G4:N%FZR9RE.01$H@`AQ2N9;3VP;P?M]&N1-.<K:<;"[N
M>O2+OUNO^KVR6I%4:9.R3CRJ7297F9''^6L5IR;"6259S#\%CN2&0*5XNZ.V
M,];JID:*5MTPC[&6^^](V9JM#TYW=PQ6*K@JZOH_(NR^"7N((*]V&5AY.+:T
MZA1;^6DK!/3A4E!<*!]=(H)@`%[S&#BE:!/2?[8(/UZ^MO`VIV<]"/9Y(Y.Q
MH_RLYL+JA:9W>=JRR=SRU=KQ$?C923?P3M<Q8>PH%6`[9/L7`Y0$P`!A4J9'
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MO2^>,17>QLBILGDEC>_UBPI,%(J;?(K+H)+B=%ND(%!XX`/**E0\]\^2,K;`
MZN^HO:B`U%VOA%*7[!L=9SOV!U<1S-AS_C^CX_-:UW2EMI5/&=2A)66C85-P
MU(JZ*CU>H)F6`QN*5M+UP]X&(-ELX8[P57],?9#CN8R/,N(5A=\PZE6&A8SK
MZK>*D)47MNMSN==(0<<HG'"D54R9@%=1,O0.[J"E:/L-;92WK:]W7N6RSE_4
M#>7)E`V&MN)X[&EIU_UFN>2X.4-38,7$N[-+_P"YHI9@<)<A$5FJ[@IE$U"C
MVB7Y4KJ1T8WFI^^./K?D6F85V4P>QIUS-2G5?V<Q'(8>MDN[+!Q,[^9K\)(O
MY!63KHHRY4`=`8H?9153Z?HZBI4W.*5KGW#AY/"&4,6[T5.-=2#+&C)WC;8N
M(C$%5WTU@*SO4EUK,DU;AY'KS%MA$LH!``3&:F5ZB!$QZYP\8Y6/RSC^P\1;
M*14ESW&5K78@*FQB4@1$GHJY<=XK^@<+[D5K9YFPLK@O*M5YZU$320:N-L+<
M1H"6EU,[`F<*.K-@S6GM[H6N0JFLFYEJLZXF\?;=:]MV]UMM;K!(^PU>&>-R
MHYVP3/G0G7%=B7RAR,E+5!+G"8K*RARI*.A5:G,5-V8Q8#B^QQ$Q,WQKS5FQ
M-;/D=T<KJ;Z_81WC$CK^X0R#^CE*`2$[9`"T8!NCFNHSY,[7>8O'2KG;C%Q0
MDT$;+;:ZJ4B4PQN2%,\1/W.$Q(4N7B)"S$CPP#AK:&CS876/\;?:=DKS_P!W
M<)RJB$`G9IQJ@G#R\HQ;S*9$*-F2&2;?CYJ,DTT&DN5$$GAF[A,CH>;,237R
M+PKGWR8>SP+?9YR`R&*,DNB,4-\C"<GY()8BSPEBT0=&,==?7RQ;6%_(WBWX
MMAI=G?\`^PUCD1">50(Y)$$@`Q=E&%^')@G"QY`4),8Y%64UZE8*+VJ5.B9'
M949,R(I.M?L]5XQ30B0I`52+@(6>DJ_96,.F5`Q2`S=R\(D0?Z5/Q=I1HV6%
MM[C9;?!?+:]QL=?)_<-^CR/&LD3/U%^](9R?[A[KFN33['06.HT&SCP%[;-J
M-K#_`&A;JD44KPSK&`"!\<F1BJ/[2]EA5[/3S%<3>2SZW:[XE:`S(1>U,8Q)
MW(EB2@`$$CV:EJO%,"%^!(9<KUN3X`4S<B8EQ<YEQH<;=[*3NZ0LQ5>__E1)
M7;^/;V,?]PJ<G;,UJOF9&9QO3P]@!G5`S_'_`,TLD$:?P+"5!_M-?@T.[MW\
ML=KA2.M&77LY*1YKYF^\.G\71$(YBN8KE&"E31K)E97;5JHH5A&5A@$4DLKW
M.'"`BH8_<W&I>'&$G*WQ]9%#&WV^!CA7R"S#H9$[F:($@&27*D^8J+(CBP'0
MX_O8\C,,7!X\O<SY$J?=[3*9X\4(A^H12=BK,RJ6$4&#$,=6:\DD9+%I9).V
MJR[ELBY;JN61DBO&Z2R:B[0RZ0+(E<I%,*B!ED3`<H&`.XH]0^.8X:.1$61E
M81O?M)!L;&QL?>QZ&WH:R\LT3R-$C*94MW`$$K<7'</47'47]1UKT<HKDIQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2O,]9,Y%F[CY!JV?,'[9=
MD^8O$$G+1XS=)&0<M7398IT7#9PB<Q#D.42G*(@("`\Y(I98)5GA9DF1@RLI
M(96!N"".H(/4$=0:XIX(<F%\;)19,>12K*P#*RL+,K*;@J02""+$&QK6ZQ):
M?7S*.V(1D]==()B5<R#!U%(OI^V:IOI5PHX>1SB);)NI.>P2H]4,JDL@4[FO
MBH8#E40Z&YG.8Z_S1CK-\D.)Y9BC"L'*QP[=4`"L')"1[`*+%6(7)L+$/<5K
M1`-M^.^6\)BR,[P7-*75D#2Y&A>1B61HU#/+JRQ[@R@OB$GN#)8UG5YB.LWM
MZ3/^L>3V%#MEU:-I-[:ZB2/N&*LN-BI%*S6R!3T7K>*L3LB1?$G+L7#";;EZ
MD^T8A?%RT(^29^HB/#.?:]\S78C%%AF[H<O#-_J&-,5+QB_4PR+)`QZ_&">Z
MK\FX?J]_./(?BW:QZ_;YR*[9&.$R<#8+;Z3EXX81S,!](R(GBR4'T_*5'95.
M2M&7!;)P>;]7(?)S!N8Q#6'%4U4+M7W)#HJ`Y>FI.4%ZA98<RJ0%(+9$TJ;N
M,)`5.4`.:N#7\:^0Y?$N0RX$S?\`3RTF@D'467Y\031/8]>YOB%NO:";"G*V
MO,3$,#G?%(=ICJ?[V!+CY,+7!NWVN<<>:.XL.Q3.;DCO8"YLIA+XPCG!WM-T
M-R$M8"E[T.F&L5U!40`Q.H$GK/9X:.;=OP(%\X"/;\!\<E9L;D$Z"+:<PPAA
M>_\`WN7,/_CBB=C_`*]M0>/F<5QI#/I?'^Q;8^H__-P,<^W_`%9YXT'^G=[=
M!5\K(;9Y4$S%8E.UCIRQC(NW<7)-<K9D=LA+VF)%+&CF>-:4NLD;H#@Q;`HB
M?Y*0HE`QHA'\;\>_K(<K?[0=0KJ<3"5O_>.YLJ<`_P`H.,"/4F]A/.GE_EA^
M"087%M*39F1US]DR_I&>Q<+&)'\Y&65/HHL":,S;<!:75AG7VQ)F7N]]EA<Q
M51B#O+_G?.%U=E(V5DUDW+E6?L\JY%$"KR+U5&-8(E`IE6Z!"$+5BZWF7E/8
M-FR&*+4X<=GF?MQ]?@0#J$!`$<2"]UC0-+(3<*[DDT9VX\>^$=6FOB$TV]V$
MW='CQELO:[3):RER&)EGD-K/-(RPPJ`"\<:@"6K58[AJV<*-UF:BZ"*RC1P*
M0N&IU4RG.W7%%15$5D#&[3=AS%[@'H(A\\QO(H21D5@R@D`B]C8^HN`;'U%P
M#_"LOPNTD2R,K(S*"5-KJ2+V-B1<>AL2+^A-5^45R4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI5-;P^%7['C\'C/Y_-V^'P]H^3R]_Z/'V=>[K
M\=/X\J7N[AV7[[]+>M_:W\:I?L[#\EOCL;W]+>][]+6]:UDURC8,MV2+DOH]
MFZTXCOD=(NU+NCC&E6*\:OSEB[C&>H6>*>P!\,C8C*=2KC`S,9*E-U$XB;KS
M/F=M^7:W18J>6M3C[+3N@$!RIXH-K''_`"F)UD^^^/\`V_<02P^E@!6K>MT/
M`MQR;-D\$;W+T_((I6.4,'&FRM'+-_,)XVB.M^:_1_M,F"<&_<2:SJWMF\-0
MZM+#B'!V9$B)&!">QYDR=Q>\<B0_:FI(5:]UNRM&+A=(.XQ$)=PF!A'H8`^.
M6@^M\2[/^KA;/;:MB>L>3BQY:C]0LV/+$6`/H6A4V]O>K^CV_G?3?T=EIM#N
ME`Z2X>;+@LUCT+P94,ZJ2.I"9#K?T('2OO\`O1MBN9-%KI:JU54`_<YFMB,8
M-H]`0((E%0\.TGI!0#*?'0C81Z?/Q_#E/^+>.$NTG*@RCV36Y18_Z=[1KZ?J
MU5?YOY>D(2+@Y1S_`#2[C!"#I[F-97/7]$JV']>WLR0T$;3?\2:UU@S<RLBT
MQ%`SN9\JBAV&%PT9V.W1L15(]Z/8`)*-8.04#O'MZF`O)"'-\0:*3_\`/PME
MOMAW65LR2/!Q+^Q:*%GF9?U#SQCIUL":BLC7>?>30WVVQT_&-45NZZZ*799]
MK=56;(2.!&Z?28\68]>ER!5/5F+U+AKK<XS&UCF;;L&S3*CDFQYL;W-IL/+-
MBF'^J?MLI0E<MB-4.IT\98IDWA`'M\9?Y>5>0LCR1E:K%R-[!%C<*8WQ8L$P
M'6H?T4XDDL)F_7YG:?UN?6J?$^+X@PMYG8O&<F?,\BH+9LVS&2NXD7_<ZY\4
M.0,<G]HQXDQ?3M'I4[>8@K/M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
(I3BE.*5__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex99-1logo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1logo2.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0.E:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C8M8S`Q-"`W.2XQ-38W.3<L(#(P,30O,#@O,C`M
M,#DZ-3,Z,#(@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z-D8P.3(S,41#,C$T,3%%-#E#,D$X0S)#,D-"
M-S,S1D(B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z-D8P.3(S,4-#,C$T
M,3%%-#E#,D$X0S)#,D-"-S,S1D(B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HY.#$R-#@Q8RUA.6,X+30R9F4M8C1E."UA
M,#@U,C%A.&9F9C<B('-T4F5F.F1O8W5M96YT240](G5U:60Z-&0T-F9A,F4M
M86)D-BTT-3ED+3DT,3`M86$W,3=D.&$W8SEE(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YG97)M86YR97EN;W-O/"]R9&8Z;&D^(#PO<F1F
M.E-E<3X@/"]D8SIC<F5A=&]R/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z
M4D1&/B`\+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_M`$A0:&]T
M;W-H;W`@,RXP`#A"24T$!```````#QP!6@`#&R5''`(```(``@`X0DE-!"4`
M`````!#\X1^)R+?)>"\T8C0'6'?K_^X`#D%D;V)E`&3``````?_;`(0``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("
M`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`&`)C
M`P$1``(1`0,1`?_$`&X``0`#``,!`0`````````````'"`D#!08$"@$!````
M`````````````````!````4#`P0"`@("`04``````0(#!`4`!@=5UA@1$A.7
M(0@4%2(6,4%A,B,E%QD1`0````````````````````#_V@`,`P$``A$#$0`_
M`/W\4"@4"@4"@4"@4"@4"@4"@4"@4"@SB^YLO%(YD^ND'>4I.H8WE%KK5O")
MAW4^F610;(M/Q3J-+;,$HZ617,7L\0"<`$?]=:"5/I<I?BED7K_9"W26R2W_
M`#)<1_W8CQ.YOZ('9^&#HLD4LE^$53X;^<._IW?ZZ4%R:"*\YOWL7AG*DC&N
MW#"08X_NQTR>M%3H.FCE&$>*(N&ZR8@=)9(Y0,4P"`@(=0H,P/KB[<RMT?6P
MV';@N>0O88UQ,_9Q%W,3+N!"W'9A*U7FF\VN9H,J[./1K^$40$W8;J'^:#9.
M@4&3F:#Q<Q]U)ZV[O896N6UAQS;3AO`8P<SAY%I*J>%-.5<-(=^S.E&HD4-Y
MU!'M`1`3`-!JXU2(W;-T$P4!-%!)),%3&.J!$TRD*"AC")C*=H?(B/41H.>@
MSR^ZZER1USXNG;FB[XF_KM%$ECY*86`]=LI-O+*=J<5*2YX]=L\-%LDS`8G_
M`'$T^\#@)BF$O4+D8DDK/EL:V8_L&6>3EGK0;0(&3D7;M](N62111`)%T^$7
MBCY%0ADU?+_,JA1`?\4$BT%3?N<TR@\PRX)C!";>+I7##+WA'VNJHA<LC9")
MUCSK.&51`S@%E@!,%/$`J^+N[0$`$!#L?J;<6);@QNY4Q$ZN@L2VG'*<U`WE
M)R4E/VS.';-OR8I?]HX=+(-Q(0%$P(<R1A,8P=!$P`%H:!0*!05$^]$S,P/U
MHON0@920AY$J]NMR/8QTJS=E2=3T>@X1*NB8BA2+I'$A@`?DHB%!!WUH,5QG
M%`<*3%P2&&8[&K)IE9.4E)=_!M\IK($61;0Z=PK*22<P7J!G/C*")0[PZ_X"
M@TLH%!DOCDD/<GV[S0QNYAEFXEH;+49_4'%I.YY6U+46(X<+G4N\K)^@R91"
MRC=/M\Q#IF*4P=O3K0:T4"@H6M*RG_T+:1'[)_\`J?\`TBHZ&+_+7_7"Y_(5
M#\@6??\`CBOT#_K[>[_F@OI0*#,S[KOB%SA]=8B3+?,C;$JC=:<];N/W$F6X
MYM!/\4Z*$8SC'35P[>)K`4P`4P&!,#?/2@OYC9A%QEA6FQA&5PQT2A",OP&%
MV&=FN9FW43\I&TX+Y9=X$DEY.U4%#F,!@Z"/Q0>WH*T_;6^GMCX3N(L*Z.UN
M:\W45CZV%$E/$N67N]ZG%^9$X"4Q#M&*BRO<`AVB0!ZT$=_2R=EHV'R;A6YI
MA><N'#=^R$0G)NW1W;B3MV8`9"(>^90ZAU$A4!8H#U'M#H%!=J@4&5V%Y9G`
M?8V5A_L4;(L/FV6OF;<8\GG4S*I8\N:W%TG#:(@8MHU6)$*-DVYA%$ADS%,I
MV%$Q5"]I@U1H%!DYFQ6+E?NG-6[=[#*]S6L&-;<=(6[B]Q.*23>4,8I$Y19E
M$/F1R1R1#F\ZG7M`1#J`T&K;1!-LT:MD@4!)NW103!8QCJ@FDF5,@*G,(F.I
MVE#N$1ZB-!]%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H((R%A%&_<L8BRB>XUXQ7%+F9<)0R<>DY2F_VZ!$1*J\.X349^#LZAVD
M/W?\4$[T"@\C?]J%OJQ[NLP[T\:2ZK=E[?-()HE<'9%EF*S(71$#G3*L9`%N
MX"B8H&Z=.H4%9+-^H[>P)W"]U6M?;QA<6+[8/9=R.@A6_P"-D>V#+*JIL9AJ
M5Z7\%9L"Y@25*942"!!Z?P"@N30*"I5Z_6Z[)?-<GFZQ<NN+!N"4M>.M15H%
MFQ%R(%CV0$%40-*/"$$[DZ11Z^,!)T^!H+8($5301365\ZQ$DR*K]A4_,J4@
M%45\91$J?D.`CVA\!UZ4'+05^SAB6_LJ-R15L9?DL=VY(PK^W[JA&=MQ,R2<
M829P!RN1X^.1TQ=_B=R`>,0**9S=?D:"0\7XZ@<36%;6/;:%R>'MF/*R;KO#
ME4>.U#**.'3QT<A2$%=VZ6.H8"@!2]W0`Z`%![Z@CG)UK7M=EO)1]A9"=8VG
M4)%!Z$XVA(V?*Y;))K)JQCEC)]4`;.!5`PG+_,#$#I\=:#QF`<$16"K?GF*,
M](W7<5X7`YNF[[GDT4&J\O,NB]ICI,FPB@T;)`)NTH"81,8PB/ST`)YH%`H%
M!#>?,1)9RQ?/8V6G5K;3FU8Q49=!DG(JMOULBVD`*5HJNW(IYA;]HB)PZ=>M
M!Y"ROKRGC[+K_)UKW8X9,+EM2(@+VL[]6B$9<,Q"LD6;2ZDER.BC'2@E;E$X
M%3.!^X_4W\QH+)T"@J+;WULO"S<MWSDRT,Q.(:/R-=S.Y;KM4]E0\BF_9M%S
M*!#I2SQX9RS*=%51/SI$*<._KTZ@%!;J@4%3[_\`KA<UQYJ3S=965W%A7$G:
MC>T0;A:$5<B'Z\BJJCDW_DWB:?>Z\@!U\?4G;U`?F@M4W(JF@@FNK^0LFBF1
M9?L*GYE2D*517QE_BGY#@(]H?`=>E!S4%9,U_7R6RG?F-LBV]D-Q85Q8S)+#
M#KI6XPN%)5Q*^,AUU4)!T@AT21(8O:8I@'OZ_P"J"?;7CYJ)MZ)CKCGANB<9
MLTT9.X!CFT0,LZ*(][P8UF8S5GY`$/X$$2ATH.^H($S'@B*S5/XV<W3*>2T;
M$FI"=D;,4CR.&5V/7+$63(DB[%RDH@V8`8Q@(4AN\3"'4*#HK`^L]MXMS%.9
M+L&0);EN7':K6W93'C&-(6)%XS6360FF[TSHRR2XF3_D3QB`B8P]?F@LQ0*"
MH"'U?N"<RG:F1,IY@F\BLL>2\C-6';:MO0T$WC'K]?SI'D7D?U6D2L!*F5,!
M`!.").X?@0$+?T"@J5>WUNNN8S9(9OL;+KFP;@D;6C[35:!9T3<B`1[,0,L(
M#)O$R=[DY2CU\?4G;\#06O;$62;H)N%OR5TT4B+N/&5+SK$(4JBWB)_%/RG`
M3=H?`=>E!S4"@4"@4"@4"@4"@4"@4"@4"@4"@A)_]B,4QKYY'/)B=3=L'2[-
MT1.Q+[<)D7;J&25*1=O;:K=<@'*/0Y#&(8/D!$*#Y.2N(=:N#U_D':]`Y*XA
MUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6
MK@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N
M#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/
M7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?
MY!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D
M':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=
MKT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO
M0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`
MY*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#D
MKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N
M(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XA
MUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6
MK@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N
M#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/
M7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?
MY!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D
M':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=
MKT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO
K0<_(S$_A\_[B>\?@_)Z_T._>[P_G?KN[L_K7?U_*^.WIW=O\NG;\T'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex99-2logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-2logo1.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0.E:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C8M8S`Q-"`W.2XQ-38W.3<L(#(P,30O,#@O,C`M
M,#DZ-3,Z,#(@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z-#(R0S8P-S)#,C$T,3%%-$%#,#(Y,T(U04,P
M,3`T0C@B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z-#(R0S8P-S%#,C$T
M,3%%-$%#,#(Y,T(U04,P,3`T0C@B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HY.#$R-#@Q8RUA.6,X+30R9F4M8C1E."UA
M,#@U,C%A.&9F9C<B('-T4F5F.F1O8W5M96YT240](G5U:60Z-&0T-F9A,F4M
M86)D-BTT-3ED+3DT,3`M86$W,3=D.&$W8SEE(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YG97)M86YR97EN;W-O/"]R9&8Z;&D^(#PO<F1F
M.E-E<3X@/"]D8SIC<F5A=&]R/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z
M4D1&/B`\+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_M`$A0:&]T
M;W-H;W`@,RXP`#A"24T$!```````#QP!6@`#&R5''`(```(``@`X0DE-!"4`
M`````!#\X1^)R+?)>"\T8C0'6'?K_^X`#D%D;V)E`&3``````?_;`(0``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("
M`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`1@"[
M`P$1``(1`0,1`?_$`*(``0`!!0$!`0`````````````(`P8'"0H$`@4!`0`!
M!`,!```````````````%`@8'"`,$"0$0```&`@$$`@$"!`(+`0````$"`P0%
M!@<(`!$2$PDA%!4B"C$R)!<C=4%10R4UM18V&+@Y.A$``@$$`0,#`P(%`@4%
M`````0(#`!$$!08A$@<Q01,B%`A1,F%"(S,6<5*!<D,D-)%BDQ4E_]H`#`,!
M``(1`Q$`/P#OXXI6.\J99QUA*DRV1,IVV)IE/A2%%[+RRXD(==41*V8,6R15
M'DG)O#AVHMFZ:BZIO@I1Z#R;X[QO><LVT6DX]C296SE/TH@]AZLQ-E5%]69B
M%'N:MOEG+^-<&T<W).69D.%IH!]4DAMU/[411=G=CT5$#,Q]`:YT=D?=UDBW
MRCFG:HTLM2C'*RC"/O%LBB6.^3ASG%)%>OTU,',3#&6`P"F1R$BN(]!$B9NI
M>;O\%_$[1:S'7:>1LK[G(4!F@A?XL>/W(DG-G>WN5^)?XL.M>;/DS\Z>3;G+
M;2>(\$8>*S%$RLA!-E2D]`8<8=T<=_8/\SGIT4]*B2YPE[6]I`)+62`V"LT=
M+E,=)2\SI:%7E$!'[B8(0<W)5M@@R$5NY'L9@E\]"#T#H&24Y7^.GC[_`+;!
MFTL$\7K]O']Q(#^TWDC65BW3ZKOW?K6'I>#?EOY7MF;/'Y%E8TWI]U+]I"1^
MX6BE>%`O6ZVC[?9?2K7?>L+V#4,Z$['X7FOO-CD.W=4F^4R1F&RAO\0#I?B+
M.5ZD8@E#J)1Z@;I_IY(1>?\`PMN`V'-M8OB8=1/CSJA_U[XNT_\`&HJ?\6/R
M+X^R[#&TD_SJ00V+EXSR*?6X^.?N%OX>AJE7MR?8=J#/M(&S6[*E>^HIVA1L
MY5^2F8A\EWF551;EMS4)("+"MU%5B\3/T$!`W3IRO-\7^$_)F&V9@8VNG[A_
MY&!(J.I]`3\)[>EO21"/7IZU1K?-7Y'>&M@FOVN9ML;L/_B[2)Y(V'J0/N%[
M[&]^Z*13U%C:U;M]/?<9BG-K^*H.=8UAA?(TBL@QC)O[RB^,K*^6-XTD$9=\
M)752?.%#`!$9`QVYC#T*Z$P@0=3_`"=^,/(N)PR;GB$C[71H"SQ]MLJ)1U)*
M+TF4#U:,!A[QVN:WH\,?FCQ+G61%Q[GT4>CY+(P5)>\G"G8]`!(WU8[$V`68
ME">@E)(%;G"F*<I3D,4Y#E`Q#E$#%,4P=2F*8.H&*8!Z@(?QYJT00;'H16[0
M(8!E-U-?7/E?:<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*Q]E7*-+
MPMCRV91R'+$A*?2XAQ,3+X2"JL*2/0B#-DV*('>24BZ4(W;(%_4LNH4@?QY-
M<=X_M>5;O&X]I(S+L\J4(B^@N?5F/\JJ+LS'H%!/M5N\MY7H^$<;S.5\CF$&
MEP83)(_J;#T55]6=V(1%'5G8`>M<LQ(G9SW(9\DIM1VM0,!T21,BD[?BLK4,
M:P"AA.FW:,@52;VO*,S'?XK@W<4J?7H=1!J5,H^A1R>`?B_PU,55&;S+,2Y"
MV$V5(/<M8F'$1NBBQO[*\A)'E`,3RE^:?D*7.9SKO'NODL&>YQ\*(];*MP,C
M.D3ZG-P!?ZFCB"BLL2>QV`-0Y]/`'K@PLSSGGI508&<SQ.0[B^R[^?1*+=XC
M34(Y$7<Z+=<QO(+(6,(@8OP5R4!/RW,?@W,_)>&>9^<]JVHX<!\D>OC<8Z+&
M>JF<L;1W%K?)\D[7]8STJ[<KR7X\\.;`>//QHT:;[R"3\4NUEC.7(\PZ,,8(
M.Z7M-[F/XL92/247-6)D#`WL%R2BG9MO=O:9KY%S**CQM7<JYM1J:H-W:13%
M;LL;4$Z<8W15!$2"B804*=,>XHF$1&8TW,/"^B8X'C/C.5NLB(A3+B8!F%P?
M5LK(NQ(O?N'0@]"!TJ!Y#X__`"*Y.@VGF3F6#QW$G!98<_9C'-F'HN%B$(`;
M6[39@0;@FY,?(?4@H.P<8N]B^M+^W(&3!BU#*U[QN[<'75!(J;&Q2[-NW!R<
MX]`(!P$PC\B`?/+TR?))^+LY!P??)K"#W'[/'R0+"]VB1B;6][5CG"\/*)OD
MXGY*XQ)N5MV+]_E8;&YM99I%47)]K]?X5D.T9GW^U8B&-8VAIS;/V!YT$6Z,
M=F)M%9?QC8V:C;PHA5,MQ9Y5W$216IOZ<?O"=(X`;P"/7K"Z_BWAGR'DOL/'
M^4VFYA#<EL(OA943`W/S8;]BNM_W?T[$7'?5Q[7FWY#>)\./5^5<)>0^/\BP
M";%8]C@S*18?;["/Y&C?M_9_5NIL?C-6^GIKCK<J'?Y!T&5-&6:.5;FR5JQD
MJR,FD_12R1C%0FJ'=I4Z,?::.JY`R1/M*$70$H`8X',5$.X?*.\\79*:7S(/
MDP'!^UVV+$QCR.WUCR($NT4X'4]@*M>X%@7J/7PIQOS7A2<C_'P_%LXR/O=%
MFS*LV+W^DN)DR62?%+74?(P=;`$]Q"5/+'?N-TI]=UXU^]7^WF=YEUM8PC:W
M6KM.Q-?F+3C+%<Q?WA)C&U%ON13G2,U<IUNQ1K8JZ#9VU9(=AW:K9'M/S0#R
MGR'1<JY]LM_QJ$P:;)F#(I4(6(15>0H.BF5PTEO7ZNO6]>J/A+BG)^$>+=/Q
M;F.0,KD.)CE9&#F0*#([1Q!SU<0QLD0;T^CZ?I`KHKYC^LJ4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE.*5SW>U*Z7C9O9#"GKXQ,Z.4[R0BK;D-=/R
M*,V\G(H+NXQ>932ZB>+HU10<S"I!^#J.4@_G*3FZGX\:K4\!X+M?-/)%':J/
M#C`V#%5(#A+_`,^1,5A!]@K>Q->='Y9;S?>4O)FC_'3B#D,\B9&81<J'<%D,
MH'\F+CA\AA[ET_F`K]+;)>5QS%X=]3ND#,T7:;K$-W&5K*S,=)_&U21*9>7D
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MV4M[,\C,R8HN4C$%4'3Y$Q.OP4Q>P+V'*?)\^JBS(6T'`N$D#[=<P(<ED/12
M(6[42X(-NR-KVZD&YQT>#^&,;=S:_)7E/E#R,&/W3X!D7$20`E@<A>^62S`C
MN#RJ1?T(L//D#'.NL3&G?9C]6>UNOU4(B@V<7_'M\L]D&)`PF,H_>,+5!)5Q
M99)ND<Y_.IT$"]!*7J!@JTN\YODSB+B_D+CFZV))(Q\G'BB[_P!%5H9#*`20
M!VC_`(GTKBY%QGQMAXQGYIXHY;QW4A0IR\/+GF^/]79,B(0D@`D][?PL+WKY
MQAC_`#-CF"4NNA.0R[IZUV=ZU@,EZYV>&%S.1R,D5,RD'DS#\@NHE'HN2]4T
M;##@EV&**@AXBB(U<@W7%MYF#5>8L+_%>=XZ&3%V<3VC8KZ28N:H!8CU;&FO
M<'M'U$6^<4X[S7C6"=Y^/VR_SCQAER+%G:>>/NE0/:\6;KG)"@BX7+Q^VQ'<
M1V`DWQOK<Y+U0ZY9&V,]3N`8'8S9V0R51,69WHA;'-[`HZK4VPM)JR2K*9QS
MC6:975JV5M\$RB2E>.4SHJ+IK*'%)($QTU\A>7N9>0,+'T6_R8LC6X4K,CI$
M(FF8`HLTH!ZN4)L`%`[CTN;UZ$^)_`GCWQ5L<KDO%L*?$W&R@59(Y)S,N.A*
MR-CPDCI&)`+EB['L7ZK"U?MQ'HAU=]E>4M9_:UN1B[+^!=HL@T;$&4-A]7X:
MTH1V/);)]4@*\A$-K/'S5?<WFO)HM(%HE(1R$@U750(1%?QN2N%5L45G.NG[
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5\*JI()G6643123*)U%53E33
M3(4.ICG.<0*0I0_B(CT#BE>+\O$]O?\`DX[L^M]SO^ZV[?J>7P?:[O+T^MY_
MT=_\O?\`'7KQ2M&GK0BFV:-N]W]PIP471$[H\Q_2'ZAE5FK2*<.E7#]RQ=.$
M_P!*:%8@(E`O0X"FBJ<@AVB7FWWGG(DXKXTXEXRQ+J3BKDSKT!+@`*&`]S+)
M,QZ=6`/K>M!/Q?Q(N;^8^=^9\_M=1G-B8KFY58RQ+LK,/000XZCKT5B"+$5B
M[!=\E:A@_>KV5O&9I++.9;]8,:X0!5$SEY%QZMC8T>FLHTH"Y$I5+$_9)&3^
M"G)#)E`>TW4;@Y=I\;9\MXAX'B?X^-ZO#CRL^QLKM\33SLWIZ1JY!]C.3ZBK
M6X%OLO3\%Y[^3LR&7E^[V$N%K.G<T:&9,;'5!]7_`%7C4KZ$8RCH#60`P6.+
M\?4O2&)M[NC-I7'<CLW[$L[LEC(V92J*&<"ZJC>P"*BR;NWRS1ZR3$1,9*)C
MU5.P_F7*I"_Y=_D&ZRO+&3C+EO'G+JN-Z]A>(3=+3&/H"(4:-SZ`S2*MQVH5
MN->!_P"*\>PO!F)F-@12ZU]WR_:*2)CCDMW0"7J>Z>198Q<DB")FLW?('D'A
M/6G(&7Z'$?1L%MTTU?.V$V+\%8.%G2LJVJK.$`+&7C-61UFTG-M[!:&?8Y/%
M-P!1)%4"NUSN._I9?*^>:;C.XE^6'&Y3Y`#?]WL,_NGQ(90?J@P<8%8S'$UT
M$S="P)C0):LA\'\8<BYGQ^$P9.9PKQ85O@ZO5]N-GY$!'T96SS2KRB:=;.8$
M^I58"9VD[JON9]>DS347$]K7M3L3C&\(@5RU9WG($AEK&D\Y11,`,K=3[<F\
M,^82"H]%SE6,*8&$Q$Q$`+R(Q?->+M&7#YWQW2;#4'H6Q\9</*C!/[H9H2O:
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MI%IM=#C*Y).G!6R@)^5R@0YB"`&ZB7N4J9VGN]6M.]M5O]LUOO#RT(XIR/.X
MER97[!6+'1[G0\@USQ#*5ZT4^W1D1/Q:Y/)T34.AX5C)J%(<QTE2D4JMD_>'
M7/$FSF"].;7;Y)QL9L3%S]AQOC>LU:Q6B1&JU@C@\S;[8]A(YW&4FJH%8NNQ
M]*+-D%S,URI"<Z8EXI6(-Q_;'Z_]#)QA3-E=B:U5\ERS9L[B<15:+LF2\M/V
MKT"F9.0QWCN'LUFCVKU(1.W6>-VR+@A1\1CB'3BE>#5'VSZ1[FNLIP^%;]=/
M^K\*TU?(63:%D3#V5<6W2L4M`.AK`M"WVHP0OF9U0%,@-5%E3'#X+T$!%2I*
M:D[9X-WAP)3-E]<+2[N>'[^M9&]7L3Z`FZPZ>JU.S2]0G2*PEB8QTNS%I/0;
ME$/*B3O`G<7J40$5*DCQ2M>NK_M.T=W(V"SCJ]KSF9O>LSZ\K32>2:R%:M$,
MV;HURU&I4^^KLY,Q#&&MD=#V84VJZ\>NNF45TC@(D4*85*G](R,?#Q[Z6EG[
M.+BHMFYD9.3D72#*/CH]DB=R\?/GKDZ39HS:-TC**JJ&*1,A1,80`!'BE:4;
MM^XD]3M2M,Y4X38.R9?7JAG87"P8%PEF?,](JB;`YB.W<O>*%1IBJGCD.@&%
MRU=N6_88#`<0ZB"E9WS/[D_7K@G63!^X=WS8]7U[V.L;FIX=O%8QSD>R+6^?
M9!/E=QR58CJL>UQJ[=Q6'R)BNV2`^=`2``B)>JE8^UQ]ZWKKVKS90M?,-WS+
M4KDW)3^2C:I'6'7+.=+AW+N(@96R/2/[-:Z'$P$00D5"N#%,Y<)%.H4J91$Y
MBE%2ICX9WHULS[L;L?JEC"Z/YS-VI[FMM<WUAQ5K'$M*RM;4%7$&#*>DXUM"
MSY72:!^X62ZX)B40-T'BE77M9B:YYHQ#*4FB64]7GG#H[A%\FL=NIU4AIF*9
M/6RO=X`E:K,2C6>CRK@*"LE$MR*&2*;S)J5`K_P8V1^MT_OY>>[R_:^O]FL_
M\>_+=W]WO-W]/[O>+^J_#_\`:W^R^SQ2K"]0U?D&VC&>(M!NX1LKG)>7(Q9F
M/P[0F6]&KT8@U["`*B:Z:Z90Z#U'OZB'\>;:_DOFP2>7-/D.RG`7`PW#>Q0Y
M$CD_H00?_2M$/PXUV1%X$Y!BQJR[1]IL$*_S"1<6%`OZ@@@?\:M3%U:"0];?
MKIB2M@?0ZVU>$U+HCXO&BLT<9JN3=XC)E``\I$;(LU1,8_\`,H0@_P"H.2/(
M,\P^=.;Y);LRAQW.$!O<@C!@*E?TO$';IZ`FHKBVL7)_&?QOB1KWX#<NUIR1
M:P*-L\D,KCW`F,:F_J0*E/D&I-;+D7<./>MB/&]US5I30[D`]J:I<9J$Q\=Z
MQ47%4H?C7AIU\51,>I3E<*E,4P&'F/=+LI,#1\8FB8J^)JMYD0>X^Z'W/:P%
MOW+\<9!]054@BU96Y%IXMGR7FF/.H>/.WG&<3)]C]B1B=Z$W_8WRRAAZ$.P(
M-ZVCE*4I0*4`*4H`4I2@`%*4`Z```'P``'->R23<^M;6@`"P]*LR[UZ>M#*-
MB(J>9PL,ZD5V]X;KQ<@\D+#37T%,QLA!5^8B[!7WM/G%9!ZU<)2I!='0(V.F
M1'O5*LBK[5+&>.JSB3'U)QE3B2Q:OC^J0-+KHV&P3ENL'X*MQR,7%DF;59Y"
M6LEAD"M4`\KM\Z<.EU!,=0YCF$14J^>*4XI7*+I/BFO^Q#WN^SS9G:"'ALEQ
M/KJME!U:U+QK:R%L%4QDY62L3JRY%CZS((*0YK/)/ZTX>-WAR'5;N954P?XC
M9HJBI758YBXQZ#0KR.8NRQ[E!ZP*Y:-UP9/&Q@,V=M`53.#9RW,'4BA.TQ!_
M@(<4KEAWY,;TB>QUC[9JI#V%QHSN@BTP][%J+3(P\FM3<M,V;UUB/8>'@&X)
M)+/IR33,R?&$Q.]TX>@)S.)9/M4K)OK6QUE%KC3<_P!].UE,.&T>T.([SDC"
M6,)WN25P'IMC>J2-KPSB-BHL0QHN3OT9`LI696(0AERF:J*$(Y.[*92J7[9W
M6NIS&F27LBRRRA\G;F[W7[*66,J9QL"+>=N+>')D&QU>$HT#*/$U7%6KS1&`
M,Y68,Q23%9<$S=R+=J1%2M_^>XZ/_LUFF5^BS_)_V<R0Q_(_61^_](]3E%CM
M/N=GV/JG61(<4^[L$Q`'IU`.*5I/_:Q__#_43_-]@O\`V+RIQ2IR>X#<U70[
MUZ;#YZ@CG4R<-8)C7!T4V37<R4WFW*3@E+QTVBV34IG+]U%S$K^4413#O,UC
MU1#ITZ\4KFWONG"GHH@_2'O5'LQ8*8K?%U8]DT\V1*=6?AMO'SJXV>\6]\H/
MVY)GC;*,Y)E;N'"ACB9O%HAT`A"@I6PG]RED&V72C>N_0:L72;I%(]CV[6-L
M(YBM55<*)/W^&TIFL(3]:;OFKI(3-)^2N,>X43Z'2=HL124$43G(HI70KA#`
MV'=;L857#6#,<U/&.,Z7$-(2`J52AF41&-VC1NFV\[HC5%,\E)O03\CIXX%5
MT[6,9590ZAC&%2N8O]T[8(#$./O5-="5F2=U_'_LYQ3>'M5H=?3D)Z7;PL?/
MV:6CJO6V0-RR]CFU4E?`V+VG=O%@`1[CB/%*VEZD>Y3".W^=:U@:F:J;\XOL
M-G8621:73.NJM@QAC6/)6H1[.ND)JXOIAXWC'<@V9'1:%.F(+N3$2Z@8X=5*
MUI^H[_\`0#^X'_SS7O\`Y7+\4KJPXI3BE:P=&&:>)]A-ZM<G1`:_C\P1^=J@
M@KT,K(T[,$,BLJ[26-XS.DHV3B2ME.T@%14'MZ_(<S_Y=E;D?"N(<XC/=WZQ
MM?,1Z+-A.0`1UL61RPZW(Z^QK5GP-CKQ#R+SWQM(.SX]RFUQP?5\?81@E@>G
M<$=%1NEE8V]Q5J8OQ7(R^#=I-*6CE-A?\#95D[EAH7ARH(IUVQ6@F<L"SC8>
MXITHE.RI+Q;DY3F%([-<HG[O@)'D'(H,;EW'O*LBE]-N-<D&=V]3\L47V&PC
M/ZN8BLJ@@7#H;6J&XKQ/(S.!\K\'0L(^0\?VSY.M[C8"&:<;352K[B/YP\#D
M$]ICD'=?H,U+3];OT=&9J<-'L=C3.=&CL9YM:`4Q)3$62*A*R"-:L4ZD8IAC
M'-+M+R0@Y5R<A?I.46#A40:H**)VJN'GZ:>3BJ,C[[49;96"?Y,S%F13+'&?
MYQ/$L<\*@GO5ID7^HZJ;X?8ZSD.-%SB1'BXQOL!,+9KZ2:_-QY'$,TH_D;&G
M:;%G<@?$ZX\C'XHV996UJ]F9$:5O(:[:$MC=$C<)1<"LJU<@12$0FZO)*F^D
M<7Z!/.K'F4^VR,)BB4Z12+*8ZS].)2V=I`TNN8W[!]4L%S_;E4?5])^D26['
MZ$$,2HRYJ]^8%36<C98-NHM\A^F')L/[L#GZ3W@=S0EODB-P05`=KHE[Q4()
MN+F3L42@4>PJ2*;M-V^=J*@)D4&$:S%Q(2+I<I1\:2"2BBG3])1Y'XVIV>8_
MQX\$A/N2"%`'J69K*H'N6(`]S4KF;W38$?RY63"HZ6`8,S$^@1%N[L?954L?
M8&OW8YZ$BP9OP:O60/&Z3@&DBW%H_;@J0#@D\:F$QVS@@#^HAOU%'X'H("'.
MG/%\$S0]R/VL1=3=3;W4^X_0^]=_&G^YQTR`CH'4'M<=KB_6S+[']0>H]#7M
MYQ5STXI7+IGK7'=#U9>S3.'LFTMUXL6YFK&[<174=QM9\9O&+7-]"R16""2/
MRSB^'D5BEN:#]RNZ=JM$`45%>3?I+D02%L\04J<^O7NBK>RN8L<88I7KX]FM
M/E;G.A$6VYY@U8?8UQMB)J5)ZHO,W^X2EF=-$V*1VI$P%B1WW'7)U$H=1!2L
M<_N8J!?<G^F_9^E8SI%PR)<9:8PF:,J5#K,W;[-)$99JH;YX=C`5YE(RKQ-D
MT;G76%-(P)))F.;H4HB"E;9L14F-M&J6,,<7N#.XB+%KW2J3<JU+MEFJJ\;+
MXWC8*PP<FS7*DX;G4:N%FZR9RE.01$H@`AQ2N9;3VP;P?M]&N1-.<K:<;"[N
M>O2+OUNO^KVR6I%4:9.R3CRJ7297F9''^6L5IR;"6259S#\%CN2&0*5XNZ.V
M,];JID:*5MTPC[&6^^](V9JM#TYW=PQ6*K@JZOH_(NR^"7N((*]V&5AY.+:T
MZA1;^6DK!/3A4E!<*!]=(H)@`%[S&#BE:!/2?[8(/UZ^MO`VIV<]"/9Y(Y.Q
MH_RLYL+JA:9W>=JRR=SRU=KQ$?C923?P3M<Q8>PH%6`[9/L7`Y0$P`!A4J9'
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MO2^>,17>QLBILGDEC>_UBPI,%(J;?(K+H)+B=%ND(%!XX`/**E0\]\^2,K;`
MZN^HO:B`U%VOA%*7[!L=9SOV!U<1S-AS_C^CX_-:UW2EMI5/&=2A)66C85-P
MU(JZ*CU>H)F6`QN*5M+UP]X&(-ELX8[P57],?9#CN8R/,N(5A=\PZE6&A8SK
MZK>*D)47MNMSN==(0<<HG'"D54R9@%=1,O0.[J"E:/L-;92WK:]W7N6RSE_4
M#>7)E`V&MN)X[&EIU_UFN>2X.4-38,7$N[-+_P"YHI9@<)<A$5FJ[@IE$U"C
MVB7Y4KJ1T8WFI^^./K?D6F85V4P>QIUS-2G5?V<Q'(8>MDN[+!Q,[^9K\)(O
MY!63KHHRY4`=`8H?9153Z?HZBI4W.*5KGW#AY/"&4,6[T5.-=2#+&C)WC;8N
M(C$%5WTU@*SO4EUK,DU;AY'KS%MA$LH!``3&:F5ZB!$QZYP\8Y6/RSC^P\1;
M*14ESW&5K78@*FQB4@1$GHJY<=XK^@<+[D5K9YFPLK@O*M5YZU$320:N-L+<
M1H"6EU,[`F<*.K-@S6GM[H6N0JFLFYEJLZXF\?;=:]MV]UMM;K!(^PU>&>-R
MHYVP3/G0G7%=B7RAR,E+5!+G"8K*RARI*.A5:G,5-V8Q8#B^QQ$Q,WQKS5FQ
M-;/D=T<KJ;Z_81WC$CK^X0R#^CE*`2$[9`"T8!NCFNHSY,[7>8O'2KG;C%Q0
MDT$;+;:ZJ4B4PQN2%,\1/W.$Q(4N7B)"S$CPP#AK:&CS876/\;?:=DKS_P!W
M<)RJB$`G9IQJ@G#R\HQ;S*9$*-F2&2;?CYJ,DTT&DN5$$GAF[A,CH>;,237R
M+PKGWR8>SP+?9YR`R&*,DNB,4-\C"<GY()8BSPEBT0=&,==?7RQ;6%_(WBWX
MMAI=G?\`^PUCD1">50(Y)$$@`Q=E&%^')@G"QY`4),8Y%64UZE8*+VJ5.B9'
M949,R(I.M?L]5XQ30B0I`52+@(6>DJ_96,.F5`Q2`S=R\(D0?Z5/Q=I1HV6%
MM[C9;?!?+:]QL=?)_<-^CR/&LD3/U%^](9R?[A[KFN33['06.HT&SCP%[;-J
M-K#_`&A;JD44KPSK&`"!\<F1BJ/[2]EA5[/3S%<3>2SZW:[XE:`S(1>U,8Q)
MW(EB2@`$$CV:EJO%,"%^!(9<KUN3X`4S<B8EQ<YEQH<;=[*3NZ0LQ5>__E1)
M7;^/;V,?]PJ<G;,UJOF9&9QO3P]@!G5`S_'_`,TLD$:?P+"5!_M-?@T.[MW\
ML=KA2.M&77LY*1YKYF^\.G\71$(YBN8KE&"E31K)E97;5JHH5A&5A@$4DLKW
M.'"`BH8_<W&I>'&$G*WQ]9%#&WV^!CA7R"S#H9$[F:($@&27*D^8J+(CBP'0
MX_O8\C,,7!X\O<SY$J?=[3*9X\4(A^H12=BK,RJ6$4&#$,=6:\DD9+%I9).V
MJR[ELBY;JN61DBO&Z2R:B[0RZ0+(E<I%,*B!ED3`<H&`.XH]0^.8X:.1$61E
M81O?M)!L;&QL?>QZ&WH:R\LT3R-$C*94MW`$$K<7'</47'47]1UKT<HKDIQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2O,]9,Y%F[CY!JV?,'[9=
MD^8O$$G+1XS=)&0<M7398IT7#9PB<Q#D.42G*(@("`\Y(I98)5GA9DF1@RLI
M(96!N"".H(/4$=0:XIX(<F%\;)19,>12K*P#*RL+,K*;@J02""+$&QK6ZQ):
M?7S*.V(1D]==()B5<R#!U%(OI^V:IOI5PHX>1SB);)NI.>P2H]4,JDL@4[FO
MBH8#E40Z&YG.8Z_S1CK-\D.)Y9BC"L'*QP[=4`"L')"1[`*+%6(7)L+$/<5K
M1`-M^.^6\)BR,[P7-*75D#2Y&A>1B61HU#/+JRQ[@R@OB$GN#)8UG5YB.LWM
MZ3/^L>3V%#MEU:-I-[:ZB2/N&*LN-BI%*S6R!3T7K>*L3LB1?$G+L7#";;EZ
MD^T8A?%RT(^29^HB/#.?:]\S78C%%AF[H<O#-_J&-,5+QB_4PR+)`QZ_&">Z
MK\FX?J]_./(?BW:QZ_;YR*[9&.$R<#8+;Z3EXX81S,!](R(GBR4'T_*5'95.
M2M&7!;)P>;]7(?)S!N8Q#6'%4U4+M7W)#HJ`Y>FI.4%ZA98<RJ0%(+9$TJ;N
M,)`5.4`.:N#7\:^0Y?$N0RX$S?\`3RTF@D'467Y\031/8]>YOB%NO:";"G*V
MO,3$,#G?%(=ICJ?[V!+CY,+7!NWVN<<>:.XL.Q3.;DCO8"YLIA+XPCG!WM-T
M-R$M8"E[T.F&L5U!40`Q.H$GK/9X:.;=OP(%\X"/;\!\<E9L;D$Z"+:<PPAA
M>_\`WN7,/_CBB=C_`*]M0>/F<5QI#/I?'^Q;8^H__-P,<^W_`%9YXT'^G=[=
M!5\K(;9Y4$S%8E.UCIRQC(NW<7)-<K9D=LA+VF)%+&CF>-:4NLD;H#@Q;`HB
M?Y*0HE`QHA'\;\>_K(<K?[0=0KJ<3"5O_>.YLJ<`_P`H.,"/4F]A/.GE_EA^
M"087%M*39F1US]DR_I&>Q<+&)'\Y&65/HHL":,S;<!:75AG7VQ)F7N]]EA<Q
M51B#O+_G?.%U=E(V5DUDW+E6?L\JY%$"KR+U5&-8(E`IE6Z!"$+5BZWF7E/8
M-FR&*+4X<=GF?MQ]?@0#J$!`$<2"]UC0-+(3<*[DDT9VX\>^$=6FOB$TV]V$
MW='CQELO:[3):RER&)EGD-K/-(RPPJ`"\<:@"6K58[AJV<*-UF:BZ"*RC1P*
M0N&IU4RG.W7%%15$5D#&[3=AS%[@'H(A\\QO(H21D5@R@D`B]C8^HN`;'U%P
M#_"LOPNTD2R,K(S*"5-KJ2+V-B1<>AL2+^A-5^45R4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI5-;P^%7['C\'C/Y_-V^'P]H^3R]_Z/'V=>[K
M\=/X\J7N[AV7[[]+>M_:W\:I?L[#\EOCL;W]+>][]+6]:UDURC8,MV2+DOH]
MFZTXCOD=(NU+NCC&E6*\:OSEB[C&>H6>*>P!\,C8C*=2KC`S,9*E-U$XB;KS
M/F=M^7:W18J>6M3C[+3N@$!RIXH-K''_`"F)UD^^^/\`V_<02P^E@!6K>MT/
M`MQR;-D\$;W+T_((I6.4,'&FRM'+-_,)XVB.M^:_1_M,F"<&_<2:SJWMF\-0
MZM+#B'!V9$B)&!">QYDR=Q>\<B0_:FI(5:]UNRM&+A=(.XQ$)=PF!A'H8`^.
M6@^M\2[/^KA;/;:MB>L>3BQY:C]0LV/+$6`/H6A4V]O>K^CV_G?3?T=EIM#N
ME`Z2X>;+@LUCT+P94,ZJ2.I"9#K?T('2OO\`O1MBN9-%KI:JU54`_<YFMB,8
M-H]`0((E%0\.TGI!0#*?'0C81Z?/Q_#E/^+>.$NTG*@RCV36Y18_Z=[1KZ?J
MU5?YOY>D(2+@Y1S_`#2[C!"#I[F-97/7]$JV']>WLR0T$;3?\2:UU@S<RLBT
MQ%`SN9\JBAV&%PT9V.W1L15(]Z/8`)*-8.04#O'MZF`O)"'-\0:*3_\`/PME
MOMAW65LR2/!Q+^Q:*%GF9?U#SQCIUL":BLC7>?>30WVVQT_&-45NZZZ*799]
MK=56;(2.!&Z?28\68]>ER!5/5F+U+AKK<XS&UCF;;L&S3*CDFQYL;W-IL/+-
MBF'^J?MLI0E<MB-4.IT\98IDWA`'M\9?Y>5>0LCR1E:K%R-[!%C<*8WQ8L$P
M'6H?T4XDDL)F_7YG:?UN?6J?$^+X@PMYG8O&<F?,\BH+9LVS&2NXD7_<ZY\4
M.0,<G]HQXDQ?3M'I4[>8@K/M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
(I3BE.*5__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex99-2logo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-2logo2.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0.E:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C8M8S`Q-"`W.2XQ-38W.3<L(#(P,30O,#@O,C`M
M,#DZ-3,Z,#(@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z-D8P.3(S,41#,C$T,3%%-#E#,D$X0S)#,D-"
M-S,S1D(B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z-D8P.3(S,4-#,C$T
M,3%%-#E#,D$X0S)#,D-"-S,S1D(B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HY.#$R-#@Q8RUA.6,X+30R9F4M8C1E."UA
M,#@U,C%A.&9F9C<B('-T4F5F.F1O8W5M96YT240](G5U:60Z-&0T-F9A,F4M
M86)D-BTT-3ED+3DT,3`M86$W,3=D.&$W8SEE(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YG97)M86YR97EN;W-O/"]R9&8Z;&D^(#PO<F1F
M.E-E<3X@/"]D8SIC<F5A=&]R/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z
M4D1&/B`\+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_M`$A0:&]T
M;W-H;W`@,RXP`#A"24T$!```````#QP!6@`#&R5''`(```(``@`X0DE-!"4`
M`````!#\X1^)R+?)>"\T8C0'6'?K_^X`#D%D;V)E`&3``````?_;`(0``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("
M`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`&`)C
M`P$1``(1`0,1`?_$`&X``0`#``,!`0`````````````'"`D#!08$"@$!````
M`````````````````!````4#`P0"`@("`04``````0(#!`4`!@=5UA@1$A.7
M(0@4%2(6,4%A,B,E%QD1`0````````````````````#_V@`,`P$``A$#$0`_
M`/W\4"@4"@4"@4"@4"@4"@4"@4"@4"@SB^YLO%(YD^ND'>4I.H8WE%KK5O")
MAW4^F610;(M/Q3J-+;,$HZ617,7L\0"<`$?]=:"5/I<I?BED7K_9"W26R2W_
M`#)<1_W8CQ.YOZ('9^&#HLD4LE^$53X;^<._IW?ZZ4%R:"*\YOWL7AG*DC&N
MW#"08X_NQTR>M%3H.FCE&$>*(N&ZR8@=)9(Y0,4P"`@(=0H,P/KB[<RMT?6P
MV';@N>0O88UQ,_9Q%W,3+N!"W'9A*U7FF\VN9H,J[./1K^$40$W8;J'^:#9.
M@4&3F:#Q<Q]U)ZV[O896N6UAQS;3AO`8P<SAY%I*J>%-.5<-(=^S.E&HD4-Y
MU!'M`1`3`-!JXU2(W;-T$P4!-%!)),%3&.J!$TRD*"AC")C*=H?(B/41H.>@
MSR^ZZER1USXNG;FB[XF_KM%$ECY*86`]=LI-O+*=J<5*2YX]=L\-%LDS`8G_
M`'$T^\#@)BF$O4+D8DDK/EL:V8_L&6>3EGK0;0(&3D7;M](N62111`)%T^$7
MBCY%0ADU?+_,JA1`?\4$BT%3?N<TR@\PRX)C!";>+I7##+WA'VNJHA<LC9")
MUCSK.&51`S@%E@!,%/$`J^+N[0$`$!#L?J;<6);@QNY4Q$ZN@L2VG'*<U`WE
M)R4E/VS.';-OR8I?]HX=+(-Q(0%$P(<R1A,8P=!$P`%H:!0*!05$^]$S,P/U
MHON0@920AY$J]NMR/8QTJS=E2=3T>@X1*NB8BA2+I'$A@`?DHB%!!WUH,5QG
M%`<*3%P2&&8[&K)IE9.4E)=_!M\IK($61;0Z=PK*22<P7J!G/C*")0[PZ_X"
M@TLH%!DOCDD/<GV[S0QNYAEFXEH;+49_4'%I.YY6U+46(X<+G4N\K)^@R91"
MRC=/M\Q#IF*4P=O3K0:T4"@H6M*RG_T+:1'[)_\`J?\`TBHZ&+_+7_7"Y_(5
M#\@6??\`CBOT#_K[>[_F@OI0*#,S[KOB%SA]=8B3+?,C;$JC=:<];N/W$F6X
MYM!/\4Z*$8SC'35P[>)K`4P`4P&!,#?/2@OYC9A%QEA6FQA&5PQT2A",OP&%
MV&=FN9FW43\I&TX+Y9=X$DEY.U4%#F,!@Z"/Q0>WH*T_;6^GMCX3N(L*Z.UN
M:\W45CZV%$E/$N67N]ZG%^9$X"4Q#M&*BRO<`AVB0!ZT$=_2R=EHV'R;A6YI
MA><N'#=^R$0G)NW1W;B3MV8`9"(>^90ZAU$A4!8H#U'M#H%!=J@4&5V%Y9G`
M?8V5A_L4;(L/FV6OF;<8\GG4S*I8\N:W%TG#:(@8MHU6)$*-DVYA%$ADS%,I
MV%$Q5"]I@U1H%!DYFQ6+E?NG-6[=[#*]S6L&-;<=(6[B]Q.*23>4,8I$Y19E
M$/F1R1R1#F\ZG7M`1#J`T&K;1!-LT:MD@4!)NW103!8QCJ@FDF5,@*G,(F.I
MVE#N$1ZB-!]%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H((R%A%&_<L8BRB>XUXQ7%+F9<)0R<>DY2F_VZ!$1*J\.X349^#LZAVD
M/W?\4$[T"@\C?]J%OJQ[NLP[T\:2ZK=E[?-()HE<'9%EF*S(71$#G3*L9`%N
MX"B8H&Z=.H4%9+-^H[>P)W"]U6M?;QA<6+[8/9=R.@A6_P"-D>V#+*JIL9AJ
M5Z7\%9L"Y@25*942"!!Z?P"@N30*"I5Z_6Z[)?-<GFZQ<NN+!N"4M>.M15H%
MFQ%R(%CV0$%40-*/"$$[DZ11Z^,!)T^!H+8($5301365\ZQ$DR*K]A4_,J4@
M%45\91$J?D.`CVA\!UZ4'+05^SAB6_LJ-R15L9?DL=VY(PK^W[JA&=MQ,R2<
M829P!RN1X^.1TQ=_B=R`>,0**9S=?D:"0\7XZ@<36%;6/;:%R>'MF/*R;KO#
ME4>.U#**.'3QT<A2$%=VZ6.H8"@!2]W0`Z`%![Z@CG)UK7M=EO)1]A9"=8VG
M4)%!Z$XVA(V?*Y;))K)JQCEC)]4`;.!5`PG+_,#$#I\=:#QF`<$16"K?GF*,
M](W7<5X7`YNF[[GDT4&J\O,NB]ICI,FPB@T;)`)NTH"81,8PB/ST`)YH%`H%
M!#>?,1)9RQ?/8V6G5K;3FU8Q49=!DG(JMOULBVD`*5HJNW(IYA;]HB)PZ=>M
M!Y"ROKRGC[+K_)UKW8X9,+EM2(@+VL[]6B$9<,Q"LD6;2ZDER.BC'2@E;E$X
M%3.!^X_4W\QH+)T"@J+;WULO"S<MWSDRT,Q.(:/R-=S.Y;KM4]E0\BF_9M%S
M*!#I2SQX9RS*=%51/SI$*<._KTZ@%!;J@4%3[_\`KA<UQYJ3S=965W%A7$G:
MC>T0;A:$5<B'Z\BJJCDW_DWB:?>Z\@!U\?4G;U`?F@M4W(JF@@FNK^0LFBF1
M9?L*GYE2D*517QE_BGY#@(]H?`=>E!S4%9,U_7R6RG?F-LBV]D-Q85Q8S)+#
M#KI6XPN%)5Q*^,AUU4)!T@AT21(8O:8I@'OZ_P"J"?;7CYJ)MZ)CKCGANB<9
MLTT9.X!CFT0,LZ*(][P8UF8S5GY`$/X$$2ATH.^H($S'@B*S5/XV<W3*>2T;
M$FI"=D;,4CR.&5V/7+$63(DB[%RDH@V8`8Q@(4AN\3"'4*#HK`^L]MXMS%.9
M+L&0);EN7':K6W93'C&-(6)%XS6360FF[TSHRR2XF3_D3QB`B8P]?F@LQ0*"
MH"'U?N"<RG:F1,IY@F\BLL>2\C-6';:MO0T$WC'K]?SI'D7D?U6D2L!*F5,!
M`!.").X?@0$+?T"@J5>WUNNN8S9(9OL;+KFP;@D;6C[35:!9T3<B`1[,0,L(
M#)O$R=[DY2CU\?4G;\#06O;$62;H)N%OR5TT4B+N/&5+SK$(4JBWB)_%/RG`
M3=H?`=>E!S4"@4"@4"@4"@4"@4"@4"@4"@4"@A)_]B,4QKYY'/)B=3=L'2[-
MT1.Q+[<)D7;J&25*1=O;:K=<@'*/0Y#&(8/D!$*#Y.2N(=:N#U_D':]`Y*XA
MUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6
MK@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N
M#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/
M7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?
MY!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D
M':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=
MKT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO
M0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`
MY*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#D
MKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N
M(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XA
MUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6
MK@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N
M#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/
M7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?
MY!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D
M':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=
MKT#DKB'6K@]?Y!VO0.2N(=:N#U_D':]`Y*XAUJX/7^0=KT#DKB'6K@]?Y!VO
K0<_(S$_A\_[B>\?@_)Z_T._>[P_G?KN[L_K7?U_*^.WIW=O\NG;\T'__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
